

**SEMMELWEIS EGYETEM  
DOKTORI ISKOLA**

**Ph.D. értekezések**

**2886.**

**JOBBÁGY ANTAL**

**Bőrgyógyászat és venerológia  
című program**

Programvezető: Dr. Sárdy Miklós, egyetemi tanár

Témavezető: Dr. Wikonkál Norbert, egyetemi tanár

Dr. Bánvölgyi András, egyetemi adjunktus

# Investigation of teledermatology and multispectral imaging as novel skin cancer screening modalities

PhD thesis

**Antal Jobbágy MD**

KÁROLY RÁCZ DOCTORAL SCHOOL OF CLINICAL MEDICINE  
Semmelweis University



Supervisor: Norbert M. Wikonkál, MD, DSc  
András Bánvölgyi MD, PhD

Official reviewers: Orsolya Németh, MD, PhD  
Nóra Belső, MD, PhD

Head of the Complex Examination Committee:  
Ádám Domonkos Tárnoki, MD, PhD

Members of the Complex Examination Committee:  
Magdolna Gaál, MD, PhD  
András Terebessy, MD, PhD

Budapest  
2023

# Table of Contents

<b>List of abbreviations .....</b>	<b>5</b>
<b>1. Introduction .....</b>	<b>6</b>
1.1. Skin cancers.....	6
1.2. Teledermatology .....	6
1.2.1. Definition of telemedicine and teledermatology .....	6
1.2.2. Teledermatology before the outbreak of the COVID-19 pandemic .....	7
1.2.3. Teledermatology after the outbreak of the COVID-19 pandemic.....	7
1.2.4. Implementation of teledermatology.....	8
1.2.5. Application of teledermatology .....	9
1.3. Dermoscopy.....	9
1.4. Multispectral imaging .....	10
1.5. Differentiation of malignant melanoma from seborrheic keratosis .....	11
<b>2. Objectives.....</b>	<b>14</b>
2.1. Project I. ....	14
2.2. Project II.....	14
<b>3. Methods.....</b>	<b>15</b>
3.1. Project I. ....	15
3.1.1. Patient data .....	15
3.1.2. Diagnostic groups .....	15
3.1.3. Triage groups.....	16
3.1.4. Statistical analyses .....	16
3.1.5. Inclusion Criteria .....	18
3.1.6. Exclusion Criteria .....	18
3.2. Project II.....	18
3.2.1. General data.....	18
3.2.2. LED-based multispectral imaging device .....	18
3.2.3. Intensity and Particle Analysis .....	19
3.2.4. SK Index.....	19
3.2.5. Statistical analysis.....	20

3.2.6.	Inclusion criteria .....	20
3.2.7.	Exclusion criteria .....	20
<b>4.</b>	<b>Results .....</b>	<b>21</b>
4.1.	Project I .....	21
4.1.1.	Inclusion and patient data.....	21
4.1.2.	Triage Groups .....	22
4.1.3.	Overall primary and aggregated diagnostic agreement .....	24
4.1.4.	Diagnostic parameters of malignant diagnostic groups .....	25
4.1.5.	Diagnostic parameters of pigmented non-malignant diagnostic groups.....	27
4.1.6.	Diagnostic parameters of non-malignant diagnostic groups .....	27
4.2.	Project II.....	29
4.2.1.	Patient data .....	29
4.2.2.	SK index.....	30
4.2.3.	Threshold optimization .....	30
<b>5.</b>	<b>Discussion .....</b>	<b>32</b>
<b>6.</b>	<b>Conclusion .....</b>	<b>38</b>
6.1.	Project I .....	38
6.2.	Project II.....	38
<b>7.</b>	<b>Summary .....</b>	<b>39</b>
<b>8.</b>	<b>References .....</b>	<b>40</b>
<b>9.</b>	<b>Bibliography of the candidate’s publications.....</b>	<b>59</b>
9.1.	Publications directly related to this thesis .....	59
9.2.	Publications not related to this thesis .....	59
<b>10.</b>	<b>Acknowledgement .....</b>	<b>61</b>

## List of abbreviations

AD	Aggregated diagnostic	NMSC	Non-melanoma skin cancer
AF	Autofluorescence	No.	Number
AK	Actinic keratosis	NPV	Negative predictive value
AUC	Area under the curve	PD	Primary diagnostic
BCC	Basal cell carcinoma	PPV	Positive predictive value
CI	Confidence interval	R	Red
COVID-19	Coronavirus disease-19	ROC	Receiver operating characteristic
EESZT	National eHealth Infrastructure system of Hungary	ROI	Region of interest
FN	False negative	SCC	Squamous cell carcinoma
FP	False positive	SD	Standard deviation
FTF	Face-to-face	SK	Seborrheic keratosis
G	Green	TD	Teledermatology
HIS	Hospital information system	TN	True negative
LED	Light-emitting diode	TP	True positive
MM	Malignant melanoma	USA	United States of America
MSI	Multispectral imaging	$\kappa$	Cohen's kappa coefficient

# **1. Introduction**

## **1.1. Skin cancers**

Skin cancer is the most common malignancy worldwide (1, 2). In the previous decades, incidence rates of skin cancers have dramatically increased in all age groups, especially among people over 60 (3, 4). Furthermore, incidence curves suggest that the incidence will continue to increase in the upcoming years (5, 6). Skin cancers are classified as non-melanoma skin cancer (NMSC) or malignant melanoma (MM) (7). Globally, it is estimated that 325.000 new cases of MM are diagnosed each year (8). The American Cancer Society predicts that by 2023, the number of new MM cases is projected to be 97.610 in the country, while mortality will reach 7.990 cases, as MM accounts for the most skin cancer deaths (9, 10). Early detection is considered effective in reducing mortality as localized MM has a significantly lower risk of metastasis and a better prognosis with a relatively high survival rate of 98% in 5 years (11). However, the survival rate decreases significantly if the patient is diagnosed with advanced (64%) or metastatic MM (23%) (12). As for NMSCs, basal cell carcinoma (BCC) is the most common skin cancer in the Caucasian population (13). Although BCCs are often not properly registered, the incidence in the United States of America (USA) is estimated at 3.6 million new cases per year (14-16). Despite the fact that metastasis from a BCC is extremely rare, locally advanced BCC's can result in significant morbidity through local destruction (17, 18). Besides BCC, cutan squamous cell carcinoma (SCC) is the second most common skin cancer with an estimated incidence of 1.8 million new cases annually in the USA (19). SCC also accounts for most NMSC-related metastatic diseases and deaths (20). Early detection is pivotal in skin cancer management if we consider increasing incidence, high mortality rates and costs of medical treatment (21). Consequently, a wide variety of imaging technologies are evolving to reform skin cancer screening (22)

## **1.2. Tele dermatology**

### **1.2.1. Definition of telemedicine and teledermatology**

The term telemedicine was used the first time by Thomas Bird in the 1970s (23, 24). It comes from the Greek word "tele" and the Latin word "medicus", which means "healing at a distance" (24, 25). Nowadays, telemedicine can be defined as the use of telecommunication

technologies to improve access to patient care and medical information (26, 27). In recent years, many subspecialty fields within medicine have already started to implement telemedicine services, such as teleradiology, telecardiology, telepathology, teleophthalmology, telepediatrics or telestroke (28-30). Dermatology is particularly suitable for telemedicine-based patient care as skin disorders are almost always visible (31). Teledermatology (TD) is a subspecialty of dermatology that has the potential to diagnose skin conditions and offer treatment from a distance (32).

### **1.2.2. Teledermatology before the outbreak of the COVID-19 pandemic**

With the advancement of telecommunication technologies, there has been a rapid development and increased use of various imaging technologies, which has made TD an emerging process in patient care (33). TD has been routinely used since the mid-2000s in Western European countries' public health care systems (34). The Netherlands individually integrated online care for dermatology patients into its health care system uniformly, while online care varies among regions in other European countries (35). In the United Kingdom, the proportion of dermatologists actively practicing TD was 17% in 2006, rising to 48% in 2016 (36). In the USA, the number of dermatology specialists varies considerably between regions. In metropolitan areas, there is an average of 4.03 dermatologists per 100 000 inhabitants, compared to 3.06 in rural areas (37). This has led to significant investment to develop TD platforms across the country in recent years, as 102 different platforms were registered in 2016, three times more than in 2011 (38).

### **1.2.3. Teledermatology after the outbreak of the COVID-19 pandemic**

After the outbreak of the COVID-19 pandemic, the role of telemedicine has undergone explosive growth all around the world in every field of medicine (39, 40). Reports suggest that some health care facilities have increased the rate of telemedicine visits from 10% before the pandemic to more than 90% during the first wave in the USA (41). Changes in outpatient care contributed to the increased use of different TD modalities, significantly minimizing the spread of COVID-19 (42). Temiz et al. (2020) were the first to publish that telemedicine could provide appropriate patient care to reduce face-to-face (FTF) consultations in dermatology at the time of the COVID-19 era (43). Most health care facilities that had not

developed their own TD system before restrictions, started to use electronic mail and various communication applications (WhatsApp, Facebook, Zoom, Skype) (44-46). A global survey was filled out by 733 dermatologists and indicated an immediate effect of the pandemic on conventional dermatology practice. The number of specialists who used TD during the first wave of the COVID-19 epidemic increased three-fold compared to the period before the outbreak of the pandemic. There was a 53% decrease in the number of specialists who provided FTF consultations, while 15.6% of respondents stopped seeing patients (47). Following the introduction of restrictions, Skayem et al. (2020) estimated that the mean number of TD consultations per day increased from 9.28 to 36.4 at their department in France, primarily for cutaneous lesions of suspected COVID-19 infections (48). In addition, the pandemic had a significant impact on dermatology residency programs. Due to the limited patient flow, various learning strategies and activities were implemented into TD care (49, 50). As for oncodermatology, TD had been already used for skin cancer screening before the pandemic yet it gained unprecedented importance after restrictions were introduced in public health care systems (51, 52).

#### **1.2.4. Implementation of teledermatology**

There are two forms of TD based on how the patient is involved in the communication process. During direct consultation session, the patients refer themselves to online care and also communicate with the dermatologist. In contrast, indirect consultation includes the communication between the referring physician (for example general practitioner) and dermatologist about the patient's condition (53, 54). In terms of technical implementation, the most widely used TD modality is asynchronous, where communication between the parties is separated by space and time (55). The asynchronous form is called "store-and-forward" TD in the literature (56). Clinical history and digital images of skin lesions are obtained by patients or the requesting clinician and then referred to a dermatologist (31). Nowadays, high-resolution digital images taken by digital cameras, mobile phones or tablets could ensure simplified use and advanced visualization of the lesions (57). In addition, a growing number of mobile phone applications are available that can provide TD care directly to patients (58-60). Therefore, store-and-forward TD may have the potential to integrate



artificial intelligence and automate the diagnostic process (61). However, the most common problem encountered in asynchronous care is the lack of relevant information, such as incomplete medical history, failure to answer relevant questions, low quality of photographs or problematic use of technology by patients (32, 62). The synchronous form is called "real-time" TD and provides limitless interaction between the parties via live video (63). Responding immediately to patients can make diagnosis faster and more efficient but also increase the amount of irrelevant information. The main limitation of the synchronous form could be the slow internet connection of the patients (56, 64). An additional problem may occur that live video is less informative than pre-submitted photographs because of its lower quality (31, 62). The hybrid form is a combination of synchronous and asynchronous TD (65). Medical history and digital images are sent to the dermatologist, followed by telephone or videoconference (66).

#### **1.2.5. Application of teledermatology**

The use of TD can facilitate the flow of medical information and help patient care in many ways. TD can reduce the number of FTF consultations for easily diagnosed and less urgent conditions as the online prescription of certain medicines is allowed (67, 68). Moreover, skin diseases can be followed up, when an already diagnosed condition or the effectiveness of the therapy is monitored (69). Therefore, TD has the potential to simplify patient care in case of autoimmune (atopic dermatitis, psoriasis) or any other chronic diseases (acne, rosacea) (70-72). Triage is one of the most common application forms, as it could improve access to dermatological care and reduce waiting time to treat urgent cases (53, 73). Therefore, TD services could allow for the early detection of skin cancers (74). The use of TD can also offer the possibility of screening elderly and disabled patients and in areas with a shortage of dermatological care (75). In addition, the combination of TD and conventional imaging techniques can ensure more reliable skin cancer screening (52).

#### **1.3. Dermoscopy**

Handheld dermoscopy has become the most commonly used noninvasive, in-vivo imaging technique in dermatology (76, 77). It allows 10x power magnification, thus provides additional details of the skin that are invisible to the naked eye (78-80). Moreover,

dermoscopy is a cost-effective and fast tool to screen patients for different skin cancers (81, 82). When one considers the pitfalls of dermoscopy, the possibility of misidentification is not to be neglected, thus its use requires extensive training (83). Accordingly, dermoscopy is not a substitute for histopathological evaluation (84). Nevertheless, certain countries encourage the dissemination of dermoscopy among general practitioners to screen patients for skin cancer or send suspected lesions for TD consultation (85, 86). Additionally, dermoscopy devices that can be attached to mobile phone cameras have also been developed. The process of referring magnified images for TD consultation is called teledermoscopy (87). Videodermoscopy is another emerging method performed by a high-resolution color video camera that offers magnification from 10 to 1000 times (88). The electronic storage allows the comparison of different images during later examinations of suspicious lesions (80). Digital dermoscopy is another method that offers a high-magnification view of extensive skin lesions (89). This technique could be an effective imaging method in preoperative mapping of skin lesions and follow-up of atypical dysplastic nevus syndrome or congenital melanocytic nevus (77, 79). First, multiple consecutive dermoscopic images are taken containing different parts of the lesion, then all records are combined (77, 90). Despite advances in dermoscopic imaging, there is a great need to develop other screening techniques that are easy to use and accessible to other health care professionals (91, 92).


#### **1.4. Multispectral imaging**

Multi-modal spectroscopy or multispectral imaging (MSI) is an emerging non-invasive technique that combines spectroscopic and other digital imaging methods (93). MSI is based on the fact that illumination of the skin with different wavelength bands of visible and infrared lights results in different pictures. When the reflected light is collected, it shows the spectral properties of the skin (94). The analysis of reflected light helps to determine the pathological and morphological features of various skin lesions (2, 95). Spectral properties of the skin are defined by organic molecules (melanin, hemoglobin, water, beta-carotene, collagen, bilirubin) called chromophores. These molecules are shown to be diverse among skin lesions of different etiologies (94, 96). In the field of dermatology, most studies have investigated the use of MSI to discriminate malignant from benign lesions (97). Others have

already reported that MSI has the potential to identify malignant lesions at a high success rate (98, 99). In addition, MSI systems that incorporate artificial intelligence-based image recognition algorithms have already been tested as a prebiopsy tool to rule out the possibility of malignancy and decrease the number of unnecessary excisions (95). This technique can be easily integrated into mobile phone cameras or serve as a standalone handheld device (100). Consequently, MSI could become a fast and cheap decision support device for the early diagnosis and management of skin cancers (101).


### **1.5. Differentiation of malignant melanoma from seborrheic keratosis**

Diagnosis of MM is among the most challenging processes in dermatology practice as it requires high levels of expertise (102). MM is caused by the malignancy of melanocytes, the risk of which is greatly increased by intermittent sun exposure (103). Besides rare forms, different main types of invasive melanoma are known, such as superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma and acral lentiginous melanoma (104-107). Similarly to NMSCs, the gold standard for the diagnosis of MM is histological examination, but visual criteria are required to perform effective screening (108). Diagnostic criteria (ABCDEs) of visual inspection to identify MM are asymmetry, border irregularity, coloration, diameter and evolution (109, 110). Most MMs contain any of the following dermoscopic criteria: atypical pigmented network, blue whitish veil, atypical vascular pattern, regression structures, irregular dots, globules, streaks or blotches (Figure 1) (111). Because of the great variety of clinical morphology, MM has the potential to contain unusual features and mimic other skin lesions (112, 113). One of the most challenging presentations of MM is the ones that clinically resemble seborrheic keratosis (SK) (114, 115).



**Figure 1. Superficial spreading melanoma (a, b) and nodular melanoma (c, d).** Dermoscopic images (b, d) show usual features of malignant melanoma: atypical pigmented network, blue whitish veil, atypical vascular pattern, irregular globules and blotches (109, 111). Clinical (a, c) and dermoscopic images were taken at the Department of Dermatology, Venereology and Dermatooncology.

SK is among the most common benign skin lesions arising from epidermal keratinocytes (116). The incidence increases with age, yet it can also occur in young individuals (117). Generally, SKs are diagnosed clinically and removed for aesthetic reason, tactile discomfort, irritation or itchiness (118, 119). SKs can appear as papules or plaques (118). Most SKs are well-demarcated with a verrucous appearance and range from light brown to black in color. The surface is most commonly keratotic, but it can be waxy, scaly, or greasy (120). SKs can also exhibit exophytic, hyperplastic or hyperpigmented variants (121). The diagnostic algorithm of SK with dermoscopy is based on the detection of sharp demarcation, moth-eaten borders, milia-like cysts and comedo-like openings. The presence of fissures and ridges, hairpin vessels, crypts, exophytic papillary structures and brown fingerprint-like structures are also among the diagnostic criteria (Figure 2) (118, 122).



**Figure 2. Macroscopic (a, c) and dermoscopic (b, d) features of seborrheic keratosis.**

Macroscopic (a) and dermoscopic images (b) of verrucous seborrheic keratosis contain fissures and ridges. Seborrheic keratosis (c, d) shows hyperpigmented areas and sharp demarcation from the skin. The dermoscopic image (d) shows milia-like cysts and comedo-like openings (120, 121). Clinical and dermoscopic images were taken at the Department of Dermatology, Venereology and Dermatooncology.

Dermoscopic features could improve diagnostic accuracy to differentiate SK from MM resembling SK (SK-like MM) (123, 124). Carrera et al. estimated that diagnostic accuracy to clinically identify SK-like MMs was 60.1% by dermatologists, while it increased to 68.1% with the involvement of dermoscopy (125). Therefore, the clinical identification of MMs from SKs with uncommon morphology can be complicated even for board-certified dermatologists (119). Misdiagnosed or delayed diagnosis of MM has a serious impact on the prognosis of the disease (126). Inappropriate management could significantly decrease the five-year survival rate of the patients (127, 128). On the top of that SKs can also resemble MMs (MM-like SK) (118, 129). In these clinically doubtful cases, histological examination is the most reliable process that can determine the correct diagnosis. However, misclassified SKs could result in unwanted psychological stress and needless excision (130).

## **2. Objectives**

### **2.1. Project I.**

The primary outcome measure was to investigate the efficacy of store-and-forward TD system for skin cancer screening during the first wave of the COVID-19 pandemic. We reviewed the outcome of TD consultations based on macroscopic images sent by the patients and matched them with the result of subsequent FTF or histopathological examinations. We aimed to assess the overall diagnostic agreement of TD care among patients referred for dermoscopic examination. We also evaluated the diagnostic parameters of different malignant and non-malignant lesions and compared them with the result of other studies before the pandemic. Another goal was to investigate the effectiveness of TD as a triage tool to refer patients with potential skin cancer for FTF examination.

### **2.2. Project II.**

Our objective was to set the most suitable threshold of a light-emitting diode (LED)-based MSI device to optimize the identification of MM from SK and SK-like MM from MM-like SK. Receiver operating characteristic (ROC) curves were performed to determine the appropriate value of the SK index as a threshold for screening.

## **3. Methods**

### **3.1. Project I.**

#### **3.1.1. Patient data**

This retrospective and single-center study focused on patients who submitted their cases via an asynchronous TD system (developed by MedInnoScan, Research and Development Ltd., Budapest, Hungary) for consultation between 25 March 2020 and 13 July 2020 at the Department of Dermatology, Venereology and Dermatoooncology, Semmelweis University (Budapest, Hungary). Our study was approved by the Ethics Committee of the National Institute of Pharmacy and Nutrition (OGYÉI/20793/2020). First, medical records of TD consultations were reviewed in the local hospital information system (HIS) (e-Medsolution, T-Systems Hungary Ltd., Budapest, Hungary) to obtain information on patients who were invited for a personal examination with a dermoscope during TD care. These documents included demographic data of the patients, one or more possible differential diagnoses of the lesion(s) and the urgency of the case determined by teledermatologists. If the dermatologists considered that the quality of the images sent by the patients were inadequate and could make it challenging to establish the correct diagnosis, it was noted as well. Digital images taken by patients in JPEG format could be uploaded with a resolution of at least 8 megapixels. Later, follow-up of patients was performed between 1 March and 30 April 2021 to collect the results of FTF or potential histopathological examinations. Data were collected from the HIS and the National eHealth Infrastructure system of Hungary (EESZT, see <http://www.eeszt.gov.hu> (accessed on 5 March 2023)). If it was necessary, patients were contacted by phone.


#### **3.1.2. Diagnostic groups**

All types of MM were categorized into one diagnostic group. Similarly, all forms of BCC and SCC were divided into two separate groups. Actinic keratoses (AKs) were also listed as malignant lesions, while the diagnostic group called “other malignancies” included skin cancers that could be classified other than the previous ones. As for non-malignant pigmented lesions, dysplastic naevi were represented as a separate group, while all other naevi were grouped together as “naevi”. SK’s, haemangiomas and warts were also defined

as different groups. All additional diagnoses with a lower number of cases were grouped into the “other lesions” group.

### 3.1.3. Triage groups

All cases were classified into three triage groups by the immediacy of the findings during TD consultations: high-urgency, moderate-urgency and low-urgency group (Figure 3). If more than one lesion was referred to TD consultation by a patient, the same triage status was assigned to both lesions, equally.



**Figure 3. Definition of the triage groups. Abbreviations: FTF, face-to-face.** The high-urgency group included cases where FTF examination was considered by teledermatologists to be warranted within a week at the latest. The medium-urgency group included cases referred for FTF examination within one month but at least one week. The low-urgency group included cases sent for dermoscopic examination after restrictions had been lifted (131).

### 3.1.4. Statistical analyses

Descriptive statistics were reported for patient demographics and lesion localizations. In this study two reference standards were defined. Histopathology was the reference standard in cases when lesions were excised. Where no histology was performed, the reference meant the result of the FTF examination. In all cases, the result of the TD examination was compared with the reference standard. Confusion matrix was used to report the number of true positive (TP), true negative (TN), false positive (FP) and false negative (FN) cases



(Table 1). Based on confusion matrix, diagnostic parameters (sensitivity, specificity, predictive values) were calculated within each diagnostic group. Cohen’s kappa coefficient ( $\kappa$ ) was assessed for each diagnostic group, separately. The concordance quantified by  $\kappa$  may indicate different strengths of agreement:  $\kappa \leq 0.2$  indicates slight agreement,  $\kappa$  of 0.21–0.40 indicates fair agreement,  $\kappa$  of 0.41–0.60 indicates moderate agreement,  $\kappa$  of 0.61–0.80 indicates substantial agreement and  $\kappa$  of 0.81–1.0 almost perfect agreement (132, 133). Overall diagnostic accuracy and  $\kappa$  value of the system were also calculated. Diagnostic agreement of all malignant and non-malignant lesions was measured, separately. All diagnostic performances were calculated based on primary and aggregated diagnoses, as well. Primary diagnostic agreement is defined as the agreement of the most possible diagnosis considered during TD consultation with the result of FTF or histological examination (134). The aggregated diagnostic agreement is the concordance of any differential diagnosis of the lesion considered during TD consultation with the reference standard (57).

**Table 1. Definition of true positive, true negative, false positive and false negative cases**  
(135, 136)

True Positive	Result of a TD consultation that correctly indicates the presence of a particular condition
True Negative	Result of a TD consultation that correctly indicates the absence of a particular condition
False Positive	Result of a TD consultation that wrongly indicates the presence of a particular condition
False Negative	Result of a TD consultation that wrongly indicates the absence of a particular condition

Abbreviations: TD: teledermatology

Pearson’s chi-square test (two-tailed) was used for categorical variables. The proportion of TP and FN diagnoses was compared among different triage groups. The distribution of confirmed malignancies and non-malignant lesions was also compared among various triage groups. Confidence intervals (95% CI) were calculated whenever appropriate. The  $p$  value below 0.0001 was considered statistically significant in all calculations. Statistical analyses were performed using Statistica v13.5.0.17 software (TIBCO Software Inc., Palo Alto, CA, USA).  $\kappa$  values were assessed using GraphPad QuickCalcs calculator (GraphPad Software Inc., San Diego, CA, USA).

### **3.1.5. Inclusion Criteria**

Later, all patients whose photographs were deemed of sufficient quality by teledermatologists and later attended personal examination with dermoscopy. Diagnostic verification of all MMs, SCCs, BCCs and other malignancies was established by histological examination. The availability of at least results from the FTF examination was an additional criterion in case of confirmed AKs and benign lesions.

### **3.1.6. Exclusion Criteria**

If teledermatologists could not determine the diagnosis due to lack of adequate photographs or absence of medical history. Patients were also excluded from the study if no follow-up information could be obtained.

## **3.2. Project II.**

### **3.2.1. General data**

Measurements were carried out at the Department of Dermatology, Venereology and Dermatooncology, Semmelweis University (Budapest, Hungary) and at the Oncology Centre of Latvia (Riga, Latvia). Our study was approved by the Institutional Ethics Committee of Semmelweis University (SE RKEB no. 228/2018) and by the Research Ethics Committee of the Institute of Cardiology and Regenerative Medicine, University of Latvia (approved on: 26 February 2019). Patients with lesions such as MM, SK, SK-like MM and MM-like SK were measured with a MSI device. Lesions were first evaluated by clinical examination and the use of handheld Heine Delta 20 (HEINE Optotechnik GmbH & Co KG, Gilching, Germany) dermoscopy by dermatologists. In cases where it was deemed necessary to remove the lesion, a histological examination was also performed.

### **3.2.2. LED-based multispectral imaging device**

We used a prototype of a handheld MSI device developed by the Biophotonics Laboratory, Institute of Atomic Physics and Spectroscopy, University of Latvia and Faculty of Computer Science and Information Technology, Riga Technical University. This device employs an illumination source with four types of LEDs (SML-LXL8047UVC, Lumex, Inc., Ronkonkoma, NY, USA) with wavelengths of 405 nm to induce skin autofluorescence (AF)

and 525 nm green (G), 660 nm red (R) and 940 nm infrared for diffuse reflectance imaging (137, 138). The lights penetrate different layers of the skin with irradiating power density of 20 mW/cm<sup>2</sup>. Images were collected with a color CMOS 5 megapixel IDS camera (MT9P006STC, IDS uEye UI3581LE-C-HQ, Obersulm, Germany). The camera was fixed from the skin at 6 cm distance with a field of view of 2 x 2 cm<sup>2</sup>. If the surface of the skin was not flat the image focus was slightly adapted by the adjustment of the region of interest (ROI). At the end of the process, all images were automatically transferred to a cloud server (139, 140). In many cases, more than one image sets were taken because of the lesions' number and size. A black marker was applied next to the captured lesions to improve the alignment of the images (area: 0.125 cm<sup>2</sup>).

### **3.2.3. Intensity and Particle Analysis**

The images were analyzed using ImageJ v1.46 software (NIH, Bethesda, MD, USA). ROI of the skin lesions were selected manually to investigate spectral reflectance and autofluorescence properties. Quantitative parameters such as mean intensity and standard deviation (SD) were analyzed in different channels (AF, G, and R). The ratio of pixels with the lowest and highest intensity values (Min/Max) of all lesions was measured within the AF channel. The intensity values of the lesions were compared with those of the adjacent control skin for normalization. AF images were converted into 8-bit form to analyze the fluorescence values of particles. Automated default thresholding process (Overlay Masks) of the ImageJ software was used to visualize the particles. The size of the particles was determined between the range of 10 and 100.000 pixels. Circularity was set between 0.4 and 1.0, while the edges were excluded. If more than one SK was in one field of view or hair affected the measurement, ROI was manually selected to specify the lesion for particle analysis. The area percentage (%) was calculated from the ratio of the area of the particles with fluorescence values above the threshold and the area of the lesion.

### **3.2.4. SK Index**

Quantitative parameters and the result of particle analysis were combined to calculate the SK index of each lesion (Figure 4).

$$\text{SK index} = \frac{2 \cdot \text{AF} \cdot \text{SD} \cdot \left(\frac{\text{Min}}{\text{Max}}\right)}{\text{G} \cdot \text{R}} + (\text{Particle number} \cdot \text{Area \%})$$

**Figure 4. Calculation of the SK index.** The mean intensity values of different channels (AF, G, and R) were included in the algorithm. In case of the AF channel, standard deviation, minimum/maximum ratio, particle number, area percentage of the particles were also added (141).

### 3.2.5. Statistical analysis

Rare forms with morphological overlaps of both MM (SK-like MM) and SK (MM-like SK) were separated from typical forms. Therefore, diagnostic parameters could be measured separately in clinically undefined cases. SK index value of all lesions was calculated, then logarithmic transformation was performed. Welch's t-test was used to compare the SK index value of MMs with SKs and SK-like MMs with MM-like SKs. ROC curves were used based on the SK index values of different lesion groups to count the area under the curves (AUC) and characterize the diagnostic performance of the LED-based MSI device. The *p* value below 0.05 was considered statistically significant in all calculations. Finally, sensitivity and specificity pairs of different cut-off points were spotted to determine the equivalent threshold, which could be uniformly suitable for the identification of both MM from SK and SK-like MM from MM-like SK. Statistical analysis was performed with the use of GraphPad Prism v8.0.1. software (GraphPad Software Inc., La Jolla, CA, USA).

### 3.2.6. Inclusion criteria

Lesions on body parts accessible to the MSI device were involved in the study. Only histologically confirmed MMs were included in the study. All SKs had to be confirmed by at least clinical and dermoscopic examination by a board-certified dermatologist.

### 3.2.7. Exclusion criteria


Clinically diagnosed MM were excluded without histological validation. Furthermore, ulcerated lesions were also excluded from the study.

## 4. Results

### 4.1. Project I.

#### 4.1.1. Inclusion and patient data

A total of 10,287 cases were submitted for TD consultation, while 749 patients with 779 lesions were included (Figure 5) as they underwent FTF dermoscopic examination.



**Figure 5. Patient selection.** 10,287 consultations were performed via store-and-forward TD. In total, 1,447 patients with 1,495 lesions were sent for dermoscopic examination. Before follow-up, lesions were excluded if teledermatologists deemed low quality of the photographs (124 patients with 124 lesions). After that HIS and EESZT were viewed and patients were called if any information could not be found about FTF examinations. After the follow-up, patients were also ruled out if they did not attend to FTF examination (491 patients with 509 lesions) or did not answer the call (83 patients with 83 lesions) (131).

Patient characteristics are shown in Table 2. The mean age of the included patients was  $43.54 \pm 21.03$  years. The median number of lesions per patient was one (interquartile range: 1–2). 45 patients (6%) had skin cancer in their personal history, 18 patients (2.4%) had it in their family history, while two patients (0.3%) had it in both. The remaining 684 patients (91.3%) had no skin cancer in their medical history.

**Table 2. Characteristics of the included patients (131)**


Variables	Number of patients
Age composition	
0-19	87 (11.6%)
20-39	225 (30.0%)
40-59	245 (32.7%)
60-79	164 (21.9%)
80≤	28 (3.7%)
Sex	
Female	474 (63.3%)
Male	275 (36.7%)
Ethnicity	
Caucasian	744 (99.3%)
Others	5 (0.7%)
Lesion location	
Head/neck	193 (24.8%)
Hand/arm	117 (15.0%)
Trunk	350 (44.9%)
Leg/foot	103 (13.2%)
Buttock/groin	16 (2.1%)

During TD consultation sessions, 639 (82%), 132 (17%) and eight lesions (1%) received a single, two and three diagnoses, respectively. Consultations were carried out by 29 dermatologist specialists and specialist registrars. The average number of completed cases per dermatologist was  $25.8 \pm 17.8$ . Dermatology residents cared for 565 patients with 586 lesions (75.2%) under the supervision of a specialist. The remaining 184 patients with 193 lesions (24.8%) were managed exclusively by a specialist.

#### **4.1.2. Triage Groups**

Figure 6 reveals the distribution of triage groups among TP and FN diagnoses. 206 lesions (26.5%) were triaged as high-urgency, 227 lesions (29.1%) as moderate-urgency, and 346

lesions (44.4%) as low-urgency by teledermatologists, respectively. In 30 cases, two separate lesions were referred to TD consultation by the same patient. The same triage status was assigned equally to both lesions.



**Figure 6. Distribution of different triage groups among true positive (Panel A) and false negative diagnoses (Panel B), considering aggregated diagnoses of the lesions during teledermatology consultations.** 156 lesions (75.7%) were diagnosed correctly in the high-urgency group, 195 (85.9%) lesions in the moderate-urgency group and 334 lesions (96.5%) in the low-urgency group, respectively. Considering misdiagnosed cases, 50 lesions (24.3%) were categorized in the high-urgency group, 32 lesions (14.1%) in the moderate-urgency group and 12 (3.5%) lesions in the low-urgency group, respectively ( $p < 0.0001$ ). After the follow-up, 87 malignancies (42.2%) and 119 benign lesions (57.7%) were confirmed in the high-urgency group, 49 malignant (21.6%) and 178 benign lesions (78.4%) in the moderate-urgency group, while 16 malignant (4.6%) and 330 benign lesions (95.4%) in the low-urgency group, respectively ( $p < 0.0001$ ) (131).

### 4.1.3. Overall primary and aggregated diagnostic agreement

Considering overall primary and aggregated diagnostic concordance of malignant lesions, substantial agreement was seen between the diagnosis of TD consultations and reference standards. In contrast, non-malignant lesions showed almost perfect agreement considering primary diagnosis, while aggregated diagnostic concordance indicated substantial agreement. The overall concordance between all TD consultations and the reference standard showed substantial agreement. Primary diagnosis of 633 lesions during TD consultations matched with the reference standard, while 146 lesions were misdiagnosed. When all differential diagnoses were included, 685 lesions matched with the reference standard, while 94 lesions failed to do so. In total, a significant difference was assessed between overall aggregated and primary diagnostic accuracy ( $p < 0.0001$ ) (Table 3).

**Table 3. Overall diagnostic agreement (131)**

PD / AD	Accuracy	Cohen's kappa
Malignant lesions		
PD	86.3% (84.1% - 88.7%)	0.647 (0.574 - 0.720)
AD	85.3% (82.9% - 87.9%)	0.644 (0.572 - 0.716)
Non-malignant lesions		
PD	81.3% (78.6% - 84.0%)	0.811 (0.790 - 0.830)
AD	86.5% (84.1% - 88.9%)	0.790 (0.769 - 0.810)
All lesions		
PD	81.2% (78.4% - 83.8%)	0.769 (0.747 - 0.792)
AD	87.9% (85.5% - 90.0%)	0.754 (0.722 - 0.776)

Abbreviations: PD: primary diagnostic, AD: aggregated diagnostic, CI: Confidence Interval.



#### **4.1.4. Diagnostic parameters of malignant diagnostic groups**

According to the primary diagnoses, the possibility of malignancy was raised in 198 lesions, while it increased to 228 lesions by involving another differential (aggregated) diagnoses. The chance of two different malignancies was considered in 12 cases during TD consultations. Later, 152 patients (female-male ratio: 48.7%-51.3%; mean age: 62.26 years  $\pm$  16.13) were diagnosed with malignancy. Histological examination confirmed the diagnosis of MM in 15 cases, BCC in 78 cases, SCC in 21 cases, other malignancies in seven cases and AK in three cases. In case of the other 28 AKs, result of the FTF examination was considered the reference standard. In the other malignancies group, all diagnoses were confirmed by histological examination: primary cutaneous follicle center lymphoma (3 lesions), invasive mammary carcinoma (1 lesion), dermatofibrosarcoma protuberans (1 lesion), metastasis of Merkel cell carcinoma (1 lesion), metastasis of adenocarcinoma (1 lesion). Considering all patients with confirmed malignancies, history of previous skin cancer was mentioned during TD consultation in 24 cases (15.8%), In comparison, at least one close relative was diagnosed with skin cancer in 6 cases (3.9%). The remaining 122 patients (80.3%) did not mention any related information during TD consultation. Sensitivity values of different malignancies ranged from 64.5% to 89.7% ( $\kappa=0.410 - 0.770$ ) according to the primary diagnoses, while sensitivity values improved to 71.4% - 93.3% ( $\kappa=0.485 - 0.714$ ) with the involvement of other differential diagnoses of the lesions (Table 4).

**Table 4. Diagnostic parameters and concordance of malignant diagnostic groups (131)**

PD / AD	No. of diagnoses during TD consultations	TP	FN	Cohen's kappa (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)	PPV (95% CI)	NPV (95% CI)
Malignant melanoma								
PD	32	10	5	0.410 (0.231 - 0.589)	66.7% (41.7% - 84.8%)	97.1% (95.7% - 98.1%)	31.3% (18.0% - 48.6%)	99.3% (98.44% - 99.7%)
AD	42	14	1	0.476 (0.317 - 0.636)	93.3% (70.2% - 99.7%)	96.3% (94.8% - 97.5%)	33.3% (21.0% - 48.5%)	99.9% (99.2% - 100.0%)
Squamous cell carcinoma								
PD	36	13	8	0.437 (0.273 - 0.600)	61.9% (40.9% - 79.3%)	97.0% (95.5% - 98.0%)	36.1% (22.5% - 52.4%)	98.9% (97.9% - 99.5%)
AD	45	19	2	0.560 (0.415-0.704)	90.5% (71.1% - 98.3%)	96.6% (95.0% - 97.7%)	42.2% (29.0% - 56.7%)	99.7% (99.0% - 100.0%)
Basal cell carcinoma								
PD	98	70	8	0.770 (0.698 - 0.842)	89.7% (81.1% - 94.7%)	96.0% (94.3% - 97.2%)	71.4% (61.8% - 79.4%)	98.8% (97.7% - 99.4%)
AD	112	71	7	0.714 (0.638 - 0.789)	91,00% (82.6% - 95.6%)	94.2% (92.2% - 95.7%)	63,4% (54.2% - 71.7%)	99,00% (97.9% - 99.5%)
Other malignancies								
PD	8	5	2	0.663 (0.386 - 0.941)	71.4% (35.9% - 94.9%)	99.6% (98.9% - 99.9%)	62.5% (30.6% - 86.3%)	99.7% (99.1% - 99.9%)
AD	8	5	2	0.663 (0.386 - 0.941)	71.4% (35.9% - 94.9%)	99.6% (98.9 - 99.9%)	62.5% (30.6% - 86.3%)	99.7% (99.1 - 100.0%)
Actinic keratosis								
PD	25	20	11	0.704 (0.566 - 0.842)	64.5% (47.0% - 78.9%)	99.3% (98.4% - 99.7%)	80.0% (60.9% - 91.1%)	98.5% (97.4% - 99.2%)
AD	33	24	7	0.739 (0.617 - 0.862)	77.4% (60.2% - 88.6%)	98.8% (97.7% - 99.4%)	72.7% (55.8% - 84.9%)	99.1% (98.1% - 99.5%)

Abbreviations: PD: primary diagnostic, AD: aggregated diagnostic, No.: number, TDC: teledermatology consultations, TP: true positive, FN: false negative, CI: confidence interval, PPV: positive predictive value, NPV: negative predictive value.

#### 4.1.5. Diagnostic parameters of pigmented non-malignant diagnostic groups

The result of the FTF examination was the gold standard in 481 cases, while histological evaluation confirmed the diagnosis in the remaining 146 cases of non-malignant lesions. In our study, the naevi diagnostic group represented itself with the highest number. Concordance of naevi indicated almost perfect agreement, while fair and moderate agreements were assessed for dysplastic naevi. In terms of all non-malignant pigmented lesions, sensitivity values ranged from 80% to 91.2% (Table 5).

**Table 5. Diagnostic parameters and concordance of dysplastic naevi and naevi groups (131)**

PD / AD	No. of diagnoses during TD consultations	TP	FN	Cohen's kappa (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)	PPV (95% CI)	NPV (95% CI)
Dysplastic naevi								
PD	38	12	3	0.437 (0.270 - 0.605)	80.0% (54.8% - 93.0%)	96.6% (95.1% - 97.7%)	31.6% (19.1% - 47.5%)	99.6% (98.8% - 99.9%)
AD	46	12	3	0.375 (0.220 - 0.530)	80.0% (54.8% - 93.0%)	95.50% (93.9% - 96.8%)	26.10% (15.6% - 40.3%)	99.6% (98.8% - 99.9%)
Naevi								
PD	265	248	37	0.848 (0.809 - 0.887)	87.0% (82.6% - 90.4%)	96.6% (94.6% - 97.8%)	93.6% (90.0% - 96.0%)	92.8% (90.2% - 94.7%)
AD	290	260	25	0.848 (0.810 - 0.887)	91.2% (87.4% - 94.0%)	93.9% (91.5% - 95.7%)	89.7% (85.6% - 92.7%)	94.9% (92.6% - 96.5%)

Abbreviations: PD: primary diagnostic, AD: aggregated diagnostic, No.: number, TDC: teledermatology consultations, TP: true positive, FN: false negative, CI: confidence interval, PPV: positive predictive value, NPV: negative predictive value.

#### 4.1.6. Diagnostic parameters of non-malignant diagnostic groups

Aggregated diagnostic concordance of other lesions ( $\kappa=0.676$ ) and SK ( $\kappa=0.780$ ) diagnostic groups indicated substantial agreement. Considering non-malignant diagnostic groups, other lesions had the lowest sensitivity (77.9%) as 15 out of 21 FN cases were diagnosed as malignant lesions during TD consultations. SKs were misdiagnosed as

malignant lesions in 14 out of 21 FN cases. In case of haemangiomas ( $\kappa=0.961$ ) and warts ( $\kappa=0.943$ ), almost perfect agreement was indicated (Table 6).

**Table 6. Diagnostic parameters and concordance of SK, haemangiomas, warts and other lesions groups (131)**


PD / AD	No. of diagnoses during TD consultations	TP	FN	Cohen's kappa (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)	PPV (95% CI)	NPV (95% CI)
Seborrheic keratosis								
PD	123	112	31	0.810 (0.754 - 0.865)	78.3% (70.9% - 84.3%)	98.3% (96.9% - 99.0%)	91.10% (84.7% - 94.9%)	95.30% (93.4% - 96.7%)
AD	154	122	21	0.780 (0.723 - 0.836)	85.3% (78.6% - 90.2%)	95.0% (93.0% - 96.4%)	79.2% (72.1% - 84.9%)	96.6% (94.9% - 97.8%)
Haemangiomas								
PD	67	65	5	0.944 (0.903 - 0.985)	92.9% (84.3% - 96.9%)	99.7% (99.0% - 100.0%)	97.0% (89.8% - 99.5%)	99.3% (98.4% - 99.7%)
AD	69	67	3	0.961 (0.926 - 0.995)	95.7% (88.1% - 98.8%)	99.7% (99.0% - 100.0%)	97.1% (90.0% - 99.5%)	99.6% (98.8% - 99.9%)
Warts								
PD	15	15	4	0.880 (0.763 - 0.996)	78.9% (56.7% - 91.5%)	100% 0,9950 to 1,000	100% (79.6% - 100.0%)	99.5% (98.7% - 99.8%)
AD	17	17	2	0.943 (0.865 - 1.000)	89.5% (68.6% - 98.1%)	100% (99.5% to 100.0%)	100% (81.6% - 100.0%)	99.7% (99.1% - 100.0%)
Other lesions								
PD	72	63	32	0.731 (0.652 - 0.810)	66.3% (56.3% - 75.0%)	98.7% (97.5% - 99.3%)	87.5% (77.9% - 93.3%)	95.5% (93.7% - 96.8%)
AD	111	74	21	0.676 (0.598 - 0.753)	77.9% (68.6% - 85.1%)	94.6% (92.6% - 96.1%)	66.7% (57.5% - 74.8%)	96.9% (95.2% - 97.9%)

Abbreviations: PD: primary diagnostic, AD: aggregated diagnostic, No.: number, TDC: teledermatology consultations, TP: true positive, FN: false negative, CI: confidence interval, PPV: positive predictive value, NPV: negative predictive value

## 4.2. Project II.

### 4.2.1. Patient data

A total of 266 patients were included in our study. The diagnosis of MM was proven in 127 cases (161 image sets) by histological examination. 66 out of all were diagnosed with superficial spreading melanoma (52 %), 18 with nodular melanoma (14.1%), 21 with in situ melanoma (16.6%), 3 with acral lentiginous melanoma (2.4%), 1 with lentigo maligna melanoma (0.8%), while 18 was unclassified (14.1%). Six patients had SK-like MM (6 image sets). The mean age of all patients with melanoma was  $64.09 \pm 13.55$  years (female-male ratio: 45.6%-54.3%). 139 patients (319 lesions with 319 image sets) were involved in the study with the diagnosis of SK. 30 patients had MM-like SK (52 image sets). The mean age of patients with all types of SK was  $70.19 \pm 11.147$  years (female-male ratio: 44.6%-55.4%). Representative images of MM, SK, SK-like MM and MM-like SK are shown in Figure 7.




**Figure 7.** Representative dermoscopic and multispectral LED images of MM (a-e), SK (f-j), SK-like MM (k-o) and MM-like SK (p-t). Dermoscopic images (a, f, k, p), red channel (b, g, l, q),

green channel (c, h, m, r), autofluorescence channel (d, i, n, s). Milia-like cysts and comedo-like openings are visualized in the autofluorescence channel as bright particles in SK (i) and MM-like SK (s) lesions. Particles are visualized in blue (j, t) with the Overlay Masks option of the ImageJ software after threshold processing (141). MSI and dermoscopic images were taken at the Department of Dermatology, Venereology and Dermatocology.

#### 4.2.2. SK index

After logarithmic transformation, SK index values of SKs were proved to be significantly higher compared to MMs. There was no significant difference between SK-like MM and MM-like SK (Figure 8).




**Figure 8.** Comparison of log SK index values - MM with SK (a) and SK-like MM with MM-like SK (b). Logarithmic transformation of the SK index values was performed. Welch's t-tests were used for statistical analysis to compare SK index values between lesion groups after logarithmic transformation. Means  $\pm$  SD:  $0.649 \pm 0.528$  (MM) vs.  $1.565 \pm 0.729$  (SK),  $p < 0.0001$  (a);  $0.745 \pm 0.747$  (SK-like MM) vs.  $1.607 \pm 0.884$  (MM-like SK),  $p = 0.06$  (b) (Unpublished results).

#### 4.2.3. Threshold optimization

Threshold determination was based on the results of ROC analyses. The selection method of the equivalent threshold was chosen to equally identify both MM from SK and SK-like MM from MM-like SK, as shown in Figure 9. The 30 value of the SK index was selected as

the optimal threshold. Lesions below this value were identified as MM or SK-like MM, while lesions above 30 were identified as SK or MM-like SK.



**Figure 9. Setting the equivalent threshold for the differentiation of both MM from SK and SK-like MM from MM-like SK.** The Area Under the Curve (AUC) was 0.844 (patients: MM, control: SK, 95% CI: 0.8085 – 0.8811,  $p < 0.0001$ ) on the MM and SK ROC curve. AUC was 0.826 (patients: SK-like MM, control: MM-like SK, 95% CI: 0.5681 – 1.000,  $p = 0.0092$ ) on ROC curve of the MM-like SK and SK-like MM comparison. Different SK index values were used to determine the optimal threshold, which could provide appropriate diagnostic parameters for the differentiation of MM from SK and MM-like SK from SK-like MM group (**a, b**). The 30 value of SK index proved to be the most suitable threshold for screening, as the sensitivity reached 91.88% (95% CI: 86.60% - 95.19%), while specificity was 57.05% (95% CI: 51.57% - 62.37%) (**a, c**). PPV was 51.76% (95% CI: 45.96% - 57.51%), while NPV reached 93.33% (95% CI: 88.93% - 96.06%). The 30 threshold was also suitable with a sensitivity of 83.3% (95% CI: 43.65% - 99.15%) and specificity of 51.9% (38.69% - 64.90%) to identify MM-like SK from SK-like MM (**b, d**). The PPV reached 16.67% (95% CI: 7.34% - 33.56%), while NPV was 96.43% (95% CI: 82.29% to 99.82%). The red diagonal dotted line represents a non-discriminatory test, the green dotted line represents appropriate diagnostic parameters with the application of the 30 values of the SK index as threshold (**c, d**) (141).

## 5. Discussion

The COVID-19 pandemic presented the world with unprecedented challenges and highlighted the importance of novel skin cancer screening technologies in early 2020 (22). Health care systems were under tremendous pressure, thus providing primary care and various skin cancer screening opportunities appeared to be challenging (142). Emergency conditions were the only exceptions (143). This situation has led to a sudden demand for the implementation of telemedicine all around the world (144). Although others have published their experiences with TD and skin cancer screening, most of these findings represented the service of teledermoscopy before the pandemic era (51, 52, 145). In our first project, the aim was to evaluate the effectiveness of a store-and-forward TD system for skin cancer screening during the first wave of the COVID-19 pandemic. Our findings characterized the use of TD in a real crisis situation, when dermatologists could rely on macroscopic images sent by the patients via a mobile phone application.

In the literature, few studies have been carried out using macroscopic images, which were most commonly taken by health care professionals. (52, 146). Moreno-Ramirez et al. (2007) investigated the efficacy of TD in a large population (890 patients), in a study similar to ours. They estimated perfect agreement ( $\kappa=0.81$ ) with the use of macroscopic images taken by digital cameras (134). Our results were close to their calculation as the overall concordance indicated substantial agreement according to both primary (81.2%,  $\kappa=0.769$ ) and aggregated diagnoses (87.9%,  $\kappa=0.754$ ). Lamel et al. (2012) was the first to evaluate the efficacy of TD based on digital images taken directly by mobile phone camera in 87 patients with 137 lesions. They measured the primary diagnostic concordance as 0.60, while the aggregated diagnostic concordance was 0.62 (147). Markun et al. (2017) reached slight agreement (77.5%,  $\kappa=0.20$ ) with the application of a mobile phone camera in 195 lesions (148). Clarke et al. (2021) took digital images of the lesions when patients applied for FTF examination in outpatient care. Later the records were sent for TD evaluation and reported moderate agreement (66.6%,  $\kappa=0.60$ ) for the primary diagnosis of 308 lesions (132). Considering these studies, the strength of agreement differs from our result, as we measured higher values. This



could be due to the lower number of participants and the different proportion of easily diagnosed and uncertain lesions in other reports.

In previous studies, overall diagnostic concordance of malignancies varied between moderate and substantial agreement ( $\kappa=0.41-0.63$ ), while accuracy ranged from 51% to 87.3% (149-151). We observed a diagnostic accuracy at the higher end compared to the literature by reaching 85.3% with substantial agreement ( $\kappa=0.644$ ). We assessed moderate agreement for MMs ( $\kappa=0.475$ ) and SCCs ( $\kappa=0.560$ ), while substantial agreement was assessed for BCCs ( $\kappa=0.714$ ) and AKs ( $\kappa=0.739$ ). This could be related to low positive predictive values as a higher number of FP than TP cases were found in the MM and SCC diagnostic groups (Table 4). Before the outbreak of the COVID-19 pandemic, Giavina-Bianchi et al. (2020) investigated the use of asynchronous TD to screen for skin cancer in Sao Paulo, Brazil (149). In this work a mobile application was designed for health care workers to send macroscopic photographs of individuals for online consultation. Our findings showed similarities with their results as substantial agreement was found in cases with BCCs ( $\kappa=0.680$ ) and AKs ( $\kappa=0.724$ ). In contrast with our results, they evaluated substantial agreement in cases of SCCs ( $\kappa=0.627$ ), while only fair agreement was estimated for MMs ( $\kappa=0.209$ ). It could be concluded that store-and-forward TD could display similar concordances of skin cancers when the image acquisition is made by patients instead of pretrained professionals.

Considering potential clinical outcomes, proper diagnosis of MM is the most essential compared to SCC and BCC (151). In case of MM (93.3%), SCC (90.5%) and BCC (91%) diagnostic groups, higher sensitivity values were estimated with the involvement of all differential diagnoses and were equivalent with other studies in the literature (52). In comparison with our findings, malignant lesions other than MMs, SCCs, BCCs or AKs have been rarely observed in studies focusing on TD (134, 151). Beer et al. (2020) emphasized during the pandemic era that widespread implementation of TD would serve as an adequate alternative for the diagnosis and follow-up of patients with rare skin cancers such as cutaneous lymphomas (152). The diagnosis of other malignancies was correctly established during TD evaluation in five patients at our department. The availability of medical history

aided the diagnosis correctly in four of these cases. All of these malignancies were eventually found to be recurring tumors. Similarly to us, others have estimated the importance of various telemedicine modalities in the follow-up of oncology patients at the time of the restrictions (153, 154).

Other studies have already highlighted that cases with suspected skin cancer can be referred to FTF examination more quickly with TD compared to conventional outpatient care system (155). This could be particularly true during the first wave of the COVID-19 pandemic, when outpatient care was limited in health care systems (156). From another point of view, the priority could not be to make the correct diagnosis in urgent cases during TD consultations, but to send patients for immediate FTF examination (157). Consequently, reduced time to attend FTF examination is associated with decreased mortality rate and lower cost of the treatment (148, 158, 159). Although the highest number of misdiagnosed cases were found in the high-urgency group, the vast majority of later confirmed MMs, SCCs and other malignancies were categorized to attend immediate FTF examination (Figure 6). In the low-urgency group, 14 of 16 cases of AK were correctly diagnosed. These patients were informed during TD consultation that they should attend FTF examination if restrictions have been lifted. After the first wave of the pandemic, the remaining two misdiagnosed superficial BCCs in the low-urgency group were removed with adequate safety margin, and no further treatment was needed. Therefore, it can be concluded that TD served as an effective triage tool in the pandemic era to send patients with skin cancer for personal examination within a short time.

Among non-malignant pigmented lesions, naevi diagnostic group reached the highest concordance ( $\kappa=0.848$ ) with a sensitivity of 91.2%. In case of dysplastic naevi, immediate FTF examination was preferred to reduce the chance of unrecognized MM. For this reason, concordance ( $\kappa=0.375$ ) for dysplastic naevi indicated only fair agreement. In contrast, most SKs were diagnosed correctly and indicated substantial agreement ( $\kappa=0.780$ ), which was better compared to the results ( $\kappa=0.513$ ) of Giavina-Bianchi et al. (2020) (149). Otherwise, similarly to other studies, we concluded that most misdiagnosed SKs were evaluated as FP diagnosis of MM or NMSC (160, 161). Taking into account all diagnostic groups,

haemangiomas showed the highest sensitivity (95.7%) and concordance ( $\kappa=0.961$ ) values. All infants were referred to FTF examination with large haemangiomas in a short term to rule out internal vascular malformations and to start the adequate therapy (Figure 6). In line with our findings, Betlloch-Mas et al. estimated very high concordance for haemangiomas ( $\kappa=0.924$ ) in pediatric TD care (162). In total, significant proportion of non-malignant lesions was correctly recognized by teledermatologists.

To the best of our knowledge, we were the first to investigate the utilization of TD for the detection of skin cancers in Central Europe. Our store-and-forward type TD provided effective skin cancer care and served as an accurate triage system during the first wave of the COVID-19 pandemic. In contrast with other studies, our findings represented a unique situation when dermatologists could only use macroscopic images taken by patients. After the pandemic, the role of TD could be essential due to the rising incidence of skin cancers and lack of dermatologists (51). From another point of view, combination of macroscopic and dermoscopic images could significantly increase diagnostic performance and reduce unnecessary FTF consultations (52, 163). High-resolution images captured by mobile phones could contribute to the integration of artificial intelligence into TD platforms, which would operate as a decision support system for dermatologists (164, 165). Furthermore, TD could increase access to dermatology care, which would provide population-based screening and alleviate the burden of health care systems (166).

In the second project, the equivalent threshold of an imaging algorithm was determined to optimize the identification of MM from SK with a LED-based MSI device. MM and SK could resemble each other in some cases, thus correct differentiation of these lesions can be complicated even for experienced dermatologists (167). Nowadays, MSI is an emerging technique, which could identify a wide variety of skin diseases (2). Besides rare skin disorders, MSI modalities are developed to serve as a potential adjunct tool to detect skin cancers (168). Setting the appropriate threshold is crucial for the effectiveness of the screening device (169). The screening method for life-threatening diseases should minimize the number of FN test results to provide high sensitivity, even if specificity is lower (170). This was a design feature of our research, as serious consequences of misdiagnosed MMs

are disproportionate to the increased number of FP cases (171, 172). The ROC analysis proved that the MSI device combined with the SK index could significantly discriminate MM from SK as AUC reached 0.844. Bratchenko et al. (2022) utilized convolutional neural network for Raman spectra analysis and obtained an AUC of 0.92 (95% CI: 0.87 - 0.97) for the classification of MM from SK. They reached sensitivity of 90 (95% CI: 0.80 – 0.97) and specificity of 83% (95% CI: 17% - 97%) (173). Although we experienced lower AUC values, direct comparison is limited, as diagnostic performance varies with different diagnostic techniques and the proportion of different lesions (174). In line with our SK index, Christensen et al. (2021) created the discrimination index to characterize lesions with a numerical variable based on the measurements of a hyperspectral imaging device. They estimated significant differences (AUC of 0.800) between MM and benign pigmented lesions, while an appropriate cut-off point was established similarly to us. Besides nevi, some SKs were also included in the benign lesion group, but a high proportion was incorrectly classified with the use of the discrimination index (175). In general, a large number of inaccurately diagnosed SKs have been already observed with different imaging modalities as lesions can manifest wide variety of morphological characteristics (176).

The clinical diagnosis is subjective, so while one dermatologist may classify a lesion as SK-like MM, another may recognize it as MM (119). Consequently, a collective threshold was chosen to ensure adequate diagnostic performance to differentiate both MMs from SKs and SK-like MMs from MM-like SKs. Despite the fact that the SK index values of SK lesions were significantly higher, determination of the threshold was challenging. This could be attributed to the large variation of the SK index values within each lesion group. Therefore, the 30 value of the SK index was chosen as the equivalent threshold, which resulted in a sensitivity of 91.88% and specificity of 57.05% for the identification of MMs from SKs. Spyridonos et al. (2021) used artificial intelligence to analyze dermoscopic images and reached a sensitivity of 78.6% and a specificity of 84.5% to differentiate directly MM from SK (119). Despite they observed lower number of FP cases, we managed to reach higher sensitivity. Other studies combined artificial intelligence with MSI and found an average sensitivity of 92.9% and specificity of 43.6%. Although the main focus of these

projects was to identify MM from naevi (177). In the future, our LED-based MSI device could be a preferable adjunct tool to decrease inter-physician variability and standardize the differentiation of MM from SK. In addition, early detection of MM with atypical morphology could reduce mortality rates and the number of unnecessary diagnostic examinations (178, 179).

## **6. Conclusion**

### **6.1. Project I.**

During the first wave of the COVID-19 pandemic, a mobile phone-based store-and-forward teledermatology system was set up at the Department of Dermatology, Venereology and Dermatooncology of Semmelweis University in Budapest, Hungary. Based on our findings the following statements can be said:

1. Teledermatology serves as an effective triage tool to refer patients with skin cancer for personal examination when outpatient care is restricted for any reason.
2. Teledermatology can ensure effective detection of MM in real crisis situations when macroscopic images are not taken by health care professionals.
3. Teledermatology enables reliable BCC and SCC screening, when access to personal visits is limited.
4. Teledermatology may be considered as an appropriate alternative of personal examination to detect benign skin lesions, such as SKs, haemangiomas and warts.

### **6.2. Project II.**

The handheld LED-based MSI device has the potential to serve as an accurate screening tool. We have come to a conclusion:

1. Determination of the appropriate threshold of the SK index algorithm is needed to optimize the differentiation of both MM from SK and SK-like MM from MM-like SK.

## 7. Summary

Skin cancers are known to be the most common malignancies in the Caucasian population (180). Furthermore, the incidence of both MM and NMSC are on the rise globally (181). Early detection of skin cancers is pivotal to decrease mortality rates and minimize health care costs (182). In the past decades, dermoscopy has become the most established non-invasive imaging method for screening (85). However, skills to use dermoscopy properly requires extensive training that makes specialists rare and may lead to limited accessibility in remote areas (183). Nowadays, various non-invasive technologies have been investigated to supplement or replace conventional methods (168). Widespread use of digital cameras and mobile phones are suitable for patients to refer suspicious skin lesions to TD consultation (184). Besides high-resolution macroscopic images, parallel assessment of dermoscopic images improves diagnostic accuracy as well (52). To sum up, several studies have already established that TD could represent a fast and cost-effective way to screen skin cancers (2). After the outbreak of the COVID-19 pandemic, an unprecedented need occurred for the implementation of TD services all around the world (185). As a result, a store-and-forward type TD service was established for the first time in the Hungarian health care when outpatient care was restricted. In our four month experience TD proved to be suitable for dermatologists to diagnose MM and NMSC with high diagnostic accuracy. From another point of view, every suspected life-threatening condition (MM, SCC and other malignancies) were sent for personal examination in a short time to confirm the diagnosis and initiate the adequate treatment. MSI is another noninvasive imaging modality that has the potential to revolutionize early recognition of skin cancers (97). MSI can be implemented into mobile phones and used as a single handheld device (186). We optimized the algorithm of a LED-based MSI device to provide high diagnostic performance for the identification of MM from SK and SK-like MM from MM-like SK. In the future, our device may serve as potential screening tool in the hands of non-expert health care professionals with the appropriate accuracy. Further investigations are also required to integrate artificial intelligence into both TD and MSI to improve efficacy and decrease the burden of the health care systems.

## 8. References

1. Gordon R. (2013) Skin cancer: an overview of epidemiology and risk factors. *Semin Oncol Nurs*, 29: 160-169.
2. Dorrell DN, Strowd LC. (2019) Skin Cancer Detection Technology. *Dermatol Clin*, 37: 527-536.
3. Bulliard JL, Cox B, Elwood JM. (1994) Latitude gradients in melanoma incidence and mortality in the non-Maori population of New Zealand. *Cancer Causes Control*, 5: 234-240.
4. Garbe C, Keim U, Gandini S, Amaral T, Katalinic A, Hollezcek B, Martus P, Flatz L, Leiter U, Whiteman D. (2021) Epidemiology of cutaneous melanoma and keratinocyte cancer in white populations 1943-2036. *Eur J Cancer*, 152: 18-25.
5. Krensell M, Petersen J, Mohr P, Weishaupt C, Augustin J, Schäfer I. (2019) Estimating prevalence and incidence of skin cancer in Germany. *J Dtsch Dermatol Ges*, 17: 1239-1249.
6. Perera E, Gnaneswaran N, Staines C, Win AK, Sinclair R. (2015) Incidence and prevalence of non-melanoma skin cancer in Australia: A systematic review. *Australas J Dermatol*, 56: 258-267.
7. Leiter U, Keim U, Garbe C. (2020) Epidemiology of Skin Cancer: Update 2019. *Adv Exp Med Biol*, 1268: 123-139.
8. Arnold M, Singh D, Laversanne M, Vignat J, Vaccarella S, Meheus F, Cust AE, de Vries E, Whiteman DC, Bray F. (2022) Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040. *JAMA Dermatology*, 158: 495-503.
9. Siegel RL, Miller KD, Wagle NS, Jemal A. (2023) Cancer statistics, 2023. *CA Cancer J Clin*, 73: 17-48.
10. Saginala K, Barsouk A, Aluru JS, Rawla P, Barsouk A. (2021) Epidemiology of Melanoma. *Med Sci (Basel)*, 9.
11. Breslow A. (1970) Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. *Ann Surg*, 172: 902-908.



12. Carr S, Smith C, Wernberg J. (2020) Epidemiology and Risk Factors of Melanoma. *Surg Clin North Am*, 100: 1-12.
13. Bánvölgyi A, Lőrincz K, Kiss N, Avci P, Fésűs L, Szipőcs R, Krenács T, Gyöngyösi N, Wikonkál N, Kárpáti S, Németh K. (2020) Efficiency of long-term high-dose intravenous ascorbic acid therapy in locally advanced basal cell carcinoma - a pilot study. *Postepy Dermatol Alergol*, 37: 548-558.
14. Krakowski AC, Hafeez F, Westheim A, Pan EY, Wilson M. (2022) Advanced basal cell carcinoma: What dermatologists need to know about diagnosis. *J Am Acad Dermatol*, 86: S1-s13.
15. Society AC. (2019) Key statistics for basal and squamous cell skin cancers.
16. Dika E, Scarfi F, Ferracin M, Broseghini E, Marcelli E, Bortolani B, Campione E, Riefolo M, Ricci C, Lambertini M. (2020) Basal Cell Carcinoma: A Comprehensive Review. *Int J Mol Sci*, 21.
17. Kim DP, Kus KJB, Ruiz E. (2019) Basal Cell Carcinoma Review. *Hematology/Oncology Clinics of North America*, 33: 13-24.
18. Cameron MC, Lee E, Hibler BP, Barker CA, Mori S, Cordova M, Nehal KS, Rossi AM. (2019) Basal cell carcinoma: Epidemiology; pathophysiology; clinical and histological subtypes; and disease associations. *J Am Acad Dermatol*, 80: 303-317.
19. Saeidi V, Doudican N, Carucci JA. (2023) Understanding the squamous cell carcinoma immune microenvironment. *Front Immunol*, 14: 1084873.
20. Combalia A, Carrera C. (2020) Squamous Cell Carcinoma: An Update on Diagnosis and Treatment. *Dermatol Pract Concept*, 10: e2020066.
21. Dildar M, Akram S, Irfan M, Khan HU, Ramzan M, Mahmood AR, Alsaiari SA, Saeed AHM, Alraddadi MO, Mahnashi MH. (2021) Skin Cancer Detection: A Review Using Deep Learning Techniques. *Int J Environ Res Public Health*, 18.
22. Giuffrida R, Conforti C, Di Meo N, Deinlein T, Guida S, Zalaudek I. (2020) Use of noninvasive imaging in the management of skin cancer. *Curr Opin Oncol*, 32: 98-105.
23. Metzger G, Jatana K, Apfeld J, Deans KJ, Minneci PC, Halaweish I. (2021) State of telemedicine use in pediatric surgery in the USA-where we stand and what we can

- gain from the COVID-19 pandemic: a scoping review. *World J Pediatr Surg*, 4: e000257.
24. Strehle EM, Shabde N. (2006) One hundred years of telemedicine: does this new technology have a place in paediatrics? *Arch Dis Child*, 91: 956-959.
  25. Kurien DVTV, M C DM, Shamsuddeen DS. (2021) AN INSIGHT INTO TELEMEDICINE : A REVIEW. *European Journal of Molecular & Clinical Medicine*, 8: 3119-3125.
  26. Petrazzuoli F, Kurpas D, Vinker S, Sarkisova V, Eleftheriou A, Żakowicz A, Aarendonk D, Ungan M. (2021) COVID-19 pandemic and the great impulse to telemedicine: the basis of the WONCA Europe Statement on Telemedicine at the WHO Europe 70th Regional Meeting September 2020. *Prim Health Care Res Dev*, 22: e80.
  27. Furlepa K, Śliwczyński A, Kamecka K, Kozłowski R, Gołębiak I, Cichońska-Rzeźnicka D, Marczak M, Glinkowski WM. (2022) The COVID-19 Pandemic as an Impulse for the Development of Telemedicine in Primary Care in Poland. *J Pers Med*, 12.
  28. Kane-Gill SL, Rincon F. (2019) Expansion of Telemedicine Services: Telepharmacy, Telestroke, Teledialysis, Tele-Emergency Medicine. *Crit Care Clin*, 35: 519-533.
  29. Venkatesh U, Aravind GP, Velmurugan AA. (2022) Telemedicine practice guidelines in India: Global implications in the wake of the COVID-19 pandemic. *World Med Health Policy*, 14: 589-599.
  30. Jafarzadeh F, Rahmani F, Azadmehr F, Falaki M, Nazari M. (2022) Different applications of telemedicine - assessing the challenges, barriers, and opportunities- a narrative review. *J Family Med Prim Care*, 11: 879-886.
  31. Lee JJ, English JC, 3rd. (2018) Teledermatology: A Review and Update. *Am J Clin Dermatol*, 19: 253-260.
  32. Pasquali P, Sonthalia S, Moreno-Ramirez D, Sharma P, Agrawal M, Gupta S, Kumar D, Arora D. (2020) Teledermatology and its Current Perspective. *Indian Dermatol Online J*, 11: 12-20.

33. Campagna M, Naka F, Lu J. (2017) Tele dermatology: An updated overview of clinical applications and reimbursement policies. *Int J Womens Dermatol*, 3: 176-179.
34. Mehrtens SH, Shall L, Halpern SM. (2019) A 14-year review of a UK tele dermatology service: experience of over 40 000 teleconsultations. *Clin Exp Dermatol*, 44: 874-881.
35. McKoy K, Halpern S, Mutyambizi K. (2021) International Tele dermatology Review. *Curr Dermatol Rep*, 10: 55-66.
36. Mehrtens SH, Halpern SM. (2018) Changing use and attitudes towards tele dermatology in the U.K. over 10 years: results of the 2016 National Survey. *Br J Dermatol*, 178: 286-288.
37. Puri P, Yiannias JA, Mangold AR, Swanson DL, Pittelkow MR. (2020) The policy dimensions, regulatory landscape, and market characteristics of tele dermatology in the United States. *JAAD Int*, 1: 202-207.
38. Yim KM, Florek AG, Oh DH, McKoy K, Armstrong AW. (2018) Tele dermatology in the United States: An Update in a Dynamic Era. *Telemed J E Health*, 24: 691-697.
39. Patel SY, Mehrotra A, Huskamp HA, Uscher-Pines L, Ganguli I, Barnett ML. (2021) Trends in Outpatient Care Delivery and Telemedicine During the COVID-19 Pandemic in the US. *JAMA Internal Medicine*, 181: 388-391.
40. Greiwe J. (2022) Telemedicine Lessons Learned During the COVID-19 Pandemic. *Curr Allergy Asthma Rep*, 22: 1-5.
41. Lonergan PE, Washington Iii SL, Branagan L, Gleason N, Pruthi RS, Carroll PR, Odisho AY. (2020) Rapid Utilization of Telehealth in a Comprehensive Cancer Center as a Response to COVID-19: Cross-Sectional Analysis. *J Med Internet Res*, 22: e19322.
42. Farr MA, Duvic M, Joshi TP. (2021) Tele dermatology During COVID-19: An Updated Review. *Am J Clin Dermatol*, 22: 467-475.
43. Temiz SA, Dursun R, Daye M, Ataseven A. (2020) Evaluation of dermatology consultations in the era of COVID-19. *Dermatologic Therapy*, 33: e13642.

44. Mostafa PIN, Hegazy AA. (2022) Dermatological consultations in the COVID-19 era: is teledermatology the key to social distancing? An Egyptian experience. *Journal of Dermatological Treatment*, 33: 910-915.
45. Gimeno-Vicente M, Alfaro-Rubio A, Gimeno-Carpio E. (2020) Teledermatology by WhatsApp in Valencia: Characteristics of Remote Consultation and Its Emotional Impact on the Dermatologist. *Actas Dermosifiliogr (Engl Ed)*, 111: 364-380.
46. Naik PP. (2022) Rise of teledermatology in the COVID-19 era: A pan-world perspective. *Digit Health*, 8: 20552076221076671.
47. Bhargava S, McKeever C, Kroumpouzou G. (2021) Impact of COVID-19 pandemic on dermatology practices: Results of a web-based, global survey. *Int J Womens Dermatol*, 7: 217-223.
48. Skayem C, Cassius C, Ben Kahla M, Fiani C, Frumholtz L, Mrad M, Petit A, Zuelgaray E, Bagot M, Bouaziz JD, Duong TA. (2020) Teledermatology for COVID-19 cutaneous lesions: substitute or supplement? *J Eur Acad Dermatol Venereol*, 34: e532-e533.
49. Ladha MA, Lui H, Carroll J, Doiron P, Kirshen C, Wong A, Purdy K. (2021) Medical Student and Resident Dermatology Education in Canada During the COVID-19 Pandemic [Formula: see text]. *J Cutan Med Surg*, 25: 437-442.
50. Oldenburg R, Marsch A. (2020) Optimizing teledermatology visits for dermatology resident education during the COVID-19 pandemic. *J Am Acad Dermatol*, 82: e229.
51. Börve A, Dahlén Gyllencreutz J, Terstappen K, Johansson Backman E, Aldenbratt A, Danielsson M, Gillstedt M, Sandberg C, Paoli J. (2015) Smartphone teledermoscopy referrals: a novel process for improved triage of skin cancer patients. *Acta Derm Venereol*, 95: 186-190.
52. Chuchu N, Dinnes J, Takwoingi Y, Martin RN, Bayliss SE, Davenport C, Moreau JF, Bassett O, Godfrey K, O'Sullivan C, Walter FM, Motley R, Deeks JJ, Williams HC. (2018) Teledermatology for diagnosing skin cancer in adults. *Cochrane Database Syst Rev*, 12: Cd013193.
53. Koch R, Polanc A, Haumann H, Kirtschig G, Martus P, Thies C, Sundmacher L, Gaa C, Witkamp L, Joos S. (2018) Improving cooperation between general practitioners

- and dermatologists via telemedicine: study protocol of the cluster-randomized controlled TeleDerm study. *Trials*, 19: 583.
54. Pathipati AS, Lee L, Armstrong AW. (2011) Health-care delivery methods in teledermatology: consultative, triage and direct-care models. *J Telemed Telecare*, 17: 214-216.
  55. López-Liria R, Valverde-Martínez M, López-Villegas A, Bautista-Mesa RJ, Vega-Ramírez FA, Peiró S, Leal-Costa C. (2022) Teledermatology versus Face-to-Face Dermatology: An Analysis of Cost-Effectiveness from Eight Studies from Europe and the United States. *Int J Environ Res Public Health*, 19.
  56. Brinker TJ, Hekler A, von Kalle C, Schadendorf D, Esser S, Berking C, Zacher MT, Sondermann W, Grabe N, Steeb T, Utikal JS, French LE, Enk AH. (2018) Teledermatology: Comparison of Store-and-Forward Versus Live Interactive Video Conferencing. *J Med Internet Res*, 20: e11871.
  57. Warshaw EM, Lederle FA, Grill JP, Gravely AA, Bangerter AK, Fortier LA, Bohjanen KA, Chen K, Lee PK, Rabinovitz HS, Johr RH, Kaye VN, Bowers S, Wenner R, Askari SK, Kedrowski DA, Nelson DB. (2009) Accuracy of teledermatology for pigmented neoplasms. *J Am Acad Dermatol*, 61: 753-765.
  58. Rizvi SMH, Schopf T, Sangha A, Ulvin K, Gjersvik P. (2020) Teledermatology in Norway using a mobile phone app. *PLoS One*, 15: e0232131.
  59. Hampton P, Richardson D, Brown S, Goodhead C, Montague K, Olivier P. (2020) Usability testing of MySkinSelfie: a mobile phone application for skin self-monitoring. *Clin Exp Dermatol*, 45: 73-78.
  60. Sondermann W, von Kalle C, Utikal JS, Schadendorf D, Esser S, Durani B, Durani H, Jansen M, Brinker TJ. (2020) [External scientific evaluation of the first teledermatology app without direct patient contact in Germany (Online Dermatologist-AppDoc)]. *Hautarzt*, 71: 887-897.
  61. Aggarwal SLP, Papay FA. (2022) Applications of multispectral and hyperspectral imaging in dermatology. *Exp Dermatol*.

62. Coates SJ, Kvedar J, Granstein RD. (2015) Tele dermatology: from historical perspective to emerging techniques of the modern era: part I: History, rationale, and current practice. *J Am Acad Dermatol*, 72: 563-574; quiz 575-566.
63. Andrees V, Klein TM, Augustin M, Otten M. (2020) Live interactive tele dermatology compared to in-person care - a systematic review. *J Eur Acad Dermatol Venereol*, 34: 733-745.
64. Pearlman RL, Le PB, Brodell RT, Nahar VK. (2021) Evaluation of patient attitudes towards the technical experience of synchronous tele dermatology in the era of COVID-19. *Arch Dermatol Res*, 313: 769-772.
65. Tensen E, van der Heijden JP, Jaspers MW, Witkamp L. (2016) Two Decades of Tele dermatology: Current Status and Integration in National Healthcare Systems. *Curr Dermatol Rep*, 5: 96-104.
66. Yi JZ, Reynolds RV, Olbricht SM, McGee JS. (2021) Moving forward with tele dermatology: Operational challenges of a hybrid in-person and virtual practice. *Clin Dermatol*, 39: 707-709.
67. Kazi R, Evankovich MR, Liu R, Liu A, Moorhead A, Ferris LK, Falo LD, Jr., English JC, 3rd. (2021) Utilization of Asynchronous and Synchronous Tele dermatology in a Large Health Care System During the COVID-19 Pandemic. *Telemed J E Health*, 27: 771-777.
68. Lim EC, Chen CY, Tan EK. (2021) Remote Prescription During Pandemic: Challenges and Solutions. *Arch Med Res*, 52: 450-452.
69. Mortimer S, Rosin A. (2021) A retrospective review of incidental malignancies in veterans seen for face-to-face follow-up after tele dermatology consultation. *J Am Acad Dermatol*, 84: 1130-1132.
70. Dahy A, El-Qushayri AE, Mahmoud AR, Al-Kelany TA, Salman S. (2020) Telemedicine approach for psoriasis management, time for application? A systematic review of published studies. *Dermatol Ther*, 33: e13908.
71. Marasca C, Annunziata MC, Camela E, Di Guida A, Fornaro L, Megna M, Napolitano M, Patruno C, Potestio L, Fabbrocini G. (2022) Tele dermatology and

- Inflammatory Skin Conditions during COVID-19 Era: New Perspectives and Applications. *J Clin Med*, 11.
72. Micali G, Dall'Oglio F, Verzì AE, Platania H, Lacarrubba F. (2022) Home treatment of single cutaneous warts combining face-to-face and teledermatology consultation: A new perspective. *Dermatol Ther*, 35: e15528.
  73. Giavina-Bianchi M, Santos AP, Cordioli E. (2020) Teledermatology reduces dermatology referrals and improves access to specialists. *EClinicalMedicine*, 29-30: 100641.
  74. Millán-Cayetano JF, Herrera-Ibarra R, Rivas-Ruiz F, García-Serrato P, García-Montero P, Blázquez-Sánchez N, Pozo-Muñoz F, de Troya-Martín M. (2020) Impact of a Community Intervention for Early Skin Cancer Diagnosis Implementing Teledermatology. *Acta Dermatovenerol Croat*, 28: 75-79.
  75. Maddukuri S, Patel J, Lipoff JB. (2021) Teledermatology Addressing Disparities in Health Care Access: a Review. *Curr Dermatol Rep*: 1-8.
  76. De Bedout V, Williams NM, Muñoz AM, Londoño AM, Munera M, Naranjo N, Rodriguez LM, Toro AM, Miao F, Koru-Sengul T, Jaimes N. (2021) Skin Cancer and Dermoscopy Training for Primary Care Physicians: A Pilot Study. *Dermatol Pract Concept*, 11: e2021145.
  77. Chen X, Lu Q, Chen C, Jiang G. (2021) Recent developments in dermoscopy for dermatology. *J Cosmet Dermatol*, 20: 1611-1617.
  78. Lallas A, Zalaudek I, Argenziano G, Longo C, Moscarella E, Di Lernia V, Al Jabhout S, Apalla Z. (2013) Dermoscopy in general dermatology. *Dermatol Clin*, 31: 679-694, x.
  79. Fink C, Haenssle HA. (2017) Non-invasive tools for the diagnosis of cutaneous melanoma. *Skin Res Technol*, 23: 261-271.
  80. Braun RP, Rabinovitz H, Tzu JE, Marghoob AA. (2009) Dermoscopy research--an update. *Semin Cutan Med Surg*, 28: 165-171.
  81. Senel E. (2011) Dermatoscopy of non-melanocytic skin tumors. *Indian J Dermatol Venereol Leprol*, 77: 16-21; quiz 22.

82. Fee JA, McGrady FP, Rosendahl C, Hart ND. (2019) Dermoscopy Use in Primary Care: A Scoping Review. *Dermatol Pract Concept*, 9: 98-104.
83. Jones OT, Jurascheck LC, Utukuri M, Pannebakker MM, Emery J, Walter FM. (2019) Dermoscopy use in UK primary care: a survey of GPs with a special interest in dermatology. *J Eur Acad Dermatol Venereol*, 33: 1706-1712.
84. Pokhrel PK, Helm MF, Greene A, Helm LA, Partin M. (2022) Dermoscopy in Primary Care. *Prim Care*, 49: 99-118.
85. Vestergaard T, Prasad SC, Schuster A, Laurinaviciene R, Bygum A, Munck A, Andersen MK. (2020) Introducing teledermoscopy of possible skin cancers in general practice in Southern Denmark. *Fam Pract*, 37: 513-518.
86. Fee JA, McGrady FP, Hart ND. (2022) Dermoscopy use in primary care: a qualitative study with general practitioners. *BMC Prim Care*, 23: 47.
87. Manahan MN, Soyer HP, Loescher LJ, Horsham C, Vagenas D, Whiteman DC, Olsen CM, Janda M. (2015) A pilot trial of mobile, patient-performed teledermoscopy. *Br J Dermatol*, 172: 1072-1080.
88. Lacarrubba F, D'Amico V, Nascia MR, Dinotta F, Micali G. (2010) Use of dermatoscopy and videodermoscopy in therapeutic follow-up: a review. *Int J Dermatol*, 49: 866-873.
89. Bleicher B, Levine A, Markowitz O. (2018) Going digital with dermoscopy. *Cutis*, 102: 102-105.
90. Ayhan E, Toprak SF. (2020) Enhancing the appearance of vessels in dermoscopic images via a mobile photo editor application. *J Am Acad Dermatol*, 82: e11-e12.
91. Sreedhar B, B.E MS, Kumar MS. A Comparative Study of Melanoma Skin Cancer Detection in Traditional and Current Image Processing Techniques. In: 2020 Fourth International Conference on I-SMAC (IoT in Social, Mobile, Analytics and Cloud) (I-SMAC), 2020: 654-658.
92. Steeb T, Reinhardt L, Strasser C, Wessely A, Schelling J, Petzold A, Heppt MV, Meier F, Berking C. (2022) The need for regular training in skin cancer screening: a cross-sectional study among general practitioners in Germany. *J Eur Acad Dermatol Venereol*.



93. Spreinat A, Selvaggio G, Erpenbeck L, Kruss S. (2020) Multispectral near infrared absorption imaging for histology of skin cancer. *J Biophotonics*, 13: e201960080.
94. Rey-Barroso L, Peña-Gutiérrez S, Yáñez C, Burgos-Fernández FJ, Vilaseca M, Royo S. (2021) Optical Technologies for the Improvement of Skin Cancer Diagnosis: A Review. *Sensors (Basel)*, 21.
95. Narayanamurthy V, Padmapriya P, Noorasafin A, Pooja B, Hema K, Firus Khan AY, Nithyakalyani K, Samsuri F. (2018) Skin cancer detection using non-invasive techniques. *RSC Adv*, 8: 28095-28130.
96. Li Q, He X, Wang Y, Liu H, Xu D, Guo F. (2013) Review of spectral imaging technology in biomedical engineering: achievements and challenges. *J Biomed Opt*, 18: 100901.
97. Monheit G, Cognetta AB, Ferris L, Rabinovitz H, Gross K, Martini M, Grichnik JM, Mihm M, Prieto VG, Googe P, King R, Toledano A, Kabelev N, Wojton M, Gutkowitz-Krusin D. (2011) The performance of MelaFind: a prospective multicenter study. *Arch Dermatol*, 147: 188-194.
98. Lihachev A, Lihacova I, Plorina EV, Lange M, Derjabo A, Spigulis J. (2018) Differentiation of seborrheic keratosis from basal cell carcinoma, nevi and melanoma by RGB autofluorescence imaging. *Biomed Opt Express*, 9: 1852-1858.
99. Vasaturo A, Di Blasio S, Verweij D, Blokk WA, van Krieken JH, de Vries IJ, Figdor CG. (2017) Multispectral imaging for highly accurate analysis of tumour-infiltrating lymphocytes in primary melanoma. *Histopathology*, 70: 643-649.
100. Kim S, Cho D, Kim J, Kim M, Youn S, Jang JE, Je M, Lee DH, Lee B, Farkas DL, Hwang JY. (2016) Smartphone-based multispectral imaging: system development and potential for mobile skin diagnosis. *Biomed Opt Express*, 7: 5294-5307.
101. Aloupogianni E, Ishikawa M, Kobayashi N, Obi T. (2022) Hyperspectral and multispectral image processing for gross-level tumor detection in skin lesions: a systematic review. *J Biomed Opt*, 27.
102. Naik PP. (2021) Cutaneous malignant melanoma: A review of early diagnosis and management. *World journal of oncology*, 12: 7.

103. Ahmed B, Qadir MI, Ghafoor S. (2020) Malignant Melanoma: Skin Cancer-Diagnosis, Prevention, and Treatment. *Crit Rev Eukaryot Gene Expr*, 30: 291-297.
104. Strashilov S, Yordanov A. (2021) Aetiology and Pathogenesis of Cutaneous Melanoma: Current Concepts and Advances. *Int J Mol Sci*, 22.
105. Bobos M. (2021) Histopathologic classification and prognostic factors of melanoma: a 2021 update. *Ital J Dermatol Venerol*, 156: 300-321.
106. Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, Bastholt L, Bataille V, Del Marmol V, Dréno B, Fargnoli MC, Forsea AM, Grob JJ, Höller C, Kaufmann R, Kelleners-Smeets N, Lallas A, Lebbé C, Lytvynenko B, Malveyh J, Moreno-Ramirez D, Nathan P, Pellacani G, Saiag P, Stratigos AJ, Van Akkooi ACJ, Vieira R, Zalaudek I, Lorigan P. (2022) European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022. *Eur J Cancer*, 170: 236-255.
107. Ferrara G, Argenziano G. (2021) The WHO 2018 Classification of Cutaneous Melanocytic Neoplasms: Suggestions From Routine Practice. *Frontiers in Oncology*, 11.
108. Majem M, Manzano JL, Marquez-Rodas I, Mujika K, Muñoz-Couselo E, Pérez-Ruiz E, de la Cruz-Merino L, Espinosa E, Gonzalez-Cao M, Berrocal A. (2021) SEOM clinical guideline for the management of cutaneous melanoma (2020). *Clinical and Translational Oncology*, 23: 948-960.
109. Hartman RI, Lin JY. (2019) Cutaneous Melanoma-A Review in Detection, Staging, and Management. *Hematol Oncol Clin North Am*, 33: 25-38.
110. Uthoff R, Song B, Maarouf M, Shi V, Liang R. (2020) Point-of-care, multispectral, smartphone-based dermoscopes for dermal lesion screening and erythema monitoring. *J Biomed Opt*, 25: 1-21.
111. Russo T, Piccolo V, Ferrara G, Agozzino M, Alfano R, Longo C, Argenziano G. (2017) Dermoscopy pathology correlation in melanoma. *J Dermatol*, 44: 507-514.
112. Szyk Ł, Scharlach C, Haenssle H, Fink C. (2021) In vivo two-photon-excited cellular fluorescence of melanin, NAD(P)H, and keratin enables an accurate differential

- diagnosis of seborrheic keratosis and pigmented cutaneous melanoma. *J Biomed Opt*, 26.
113. Banerjee SS, Eyden B. (2008) Divergent differentiation in malignant melanomas: a review. *Histopathology*, 52: 119-129.
  114. Argenziano G, Rossiello L, Scalvenzi M, Staibano S, Ruocco E, Cicale L, Soyer HP. (2003) Melanoma simulating seborrheic keratosis: a major dermoscopy pitfall. *Arch Dermatol*, 139: 389-391.
  115. Papageorgiou V, Apalla Z, Sotiriou E, Papageorgiou C, Lazaridou E, Vakirlis S, Ioannides D, Lallas A. (2018) The limitations of dermoscopy: false-positive and false-negative tumours. *J Eur Acad Dermatol Venereol*, 32: 879-888.
  116. Moscarella E, Brancaccio G, Briatico G, Ronchi A, Piana S, Argenziano G. (2021) Differential Diagnosis and Management on Seborrheic Keratosis in Elderly Patients. *Clin Cosmet Investig Dermatol*, 14: 395-406.
  117. Barthelmann S, Butsch F, Lang BM, Stege H, Großmann B, Schepler H, Grabbe S. (2023) Seborrheic keratosis. *J Dtsch Dermatol Ges*, 21: 265-277.
  118. Sun MD, Halpern AC. (2022) Advances in the Etiology, Detection, and Clinical Management of Seborrheic Keratoses. *Dermatology*, 238: 205-217.
  119. Spyridonos P, Gaitanis G, Likas A, Bassukas I. (2021) Characterizing Malignant Melanoma Clinically Resembling Seborrheic Keratosis Using Deep Knowledge Transfer. *Cancers (Basel)*, 13.
  120. Jackson JM, Alexis A, Berman B, Berson DS, Taylor S, Weiss JS. (2015) Current Understanding of Seborrheic Keratosis: Prevalence, Etiology, Clinical Presentation, Diagnosis, and Management. *J Drugs Dermatol*, 14: 1119-1125.
  121. Braun RP, Ludwig S, Marghoob AA. (2017) Differential Diagnosis of Seborrheic Keratosis: Clinical and Dermoscopic Features. *J Drugs Dermatol*, 16: 835-842.
  122. Gülseren D, Hofmann-Wellenhof R. (2019) Evaluation of dermoscopic criteria for seborrheic keratosis on non-polarized versus polarized dermoscopy. *Skin Res Technol*, 25: 801-804.
  123. Carrera C, Segura S, Aguilera P, Scalvenzi M, Longo C, Barreiro A, Broganelli P, Cavicchini S, Llambrich A, Zaballos P, Thomas L, Malveyh J, Puig S, Zalaudek I.

- (2017) Dermoscopic Clues for Diagnosing Melanomas That Resemble Seborrheic Keratosis. *JAMA Dermatol*, 153: 544-551.
124. Dinnes J, Deeks JJ, Chuchu N, Ferrante di Ruffano L, Matin RN, Thomson DR, Wong KY, Aldridge RB, Abbott R, Fawzy M, Bayliss SE, Grainge MJ, Takwoingi Y, Davenport C, Godfrey K, Walter FM, Williams HC. (2018) Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults. *Cochrane Database Syst Rev*, 12: Cd011902.
  125. Carrera C, Segura S, Aguilera P, Takigami CM, Gomes A, Barreiro A, Scalvenzi M, Longo C, Cavicchini S, Thomas L, Malveyh J, Puig S, Zalaudek I. (2017) Dermoscopy Improves the Diagnostic Accuracy of Melanomas Clinically Resembling Seborrheic Keratosis: Cross-Sectional Study of the Ability to Detect Seborrheic Keratosis-Like Melanomas by a Group of Dermatologists with Varying Degrees of Experience. *Dermatology*, 233: 471-479.
  126. Davis LE, Shalin SC, Tackett AJ. (2019) Current state of melanoma diagnosis and treatment. *Cancer Biology & Therapy*, 20: 1366-1379.
  127. Rogiers A, Boekhout A, Schwarze JK, Awada G, Blank CU, Neyns B. (2019) Long-Term Survival, Quality of Life, and Psychosocial Outcomes in Advanced Melanoma Patients Treated with Immune Checkpoint Inhibitors. *Journal of Oncology*, 2019: 5269062.
  128. Yang J, Pan Z, Zhou Q, Liu Q, Zhao F, Feng X, Lyu J. (2019) Nomogram for predicting the survival of patients with malignant melanoma: A population analysis. *Oncology letters*, 18: 3591-3598.
  129. De Giorgi V, Massi D, Stante M, Carli P. (2002) False “Melanocytic” Parameters Shown by Pigmented Seborrheic Keratoses: A Finding Which is not Uncommon in Dermoscopy. *Dermatologic Surgery*, 28: 776-779.
  130. Farnetani F, Pedroni G, Lippolis N, Giovani M, Ciardo S, Chester J, Kaleci S, Pezzini C, Cantisani C, Dattola A, Manfredini M, Dika E, Patrizi A, Pellacani G. (2021) Facial seborrheic keratosis with unusual dermoscopic patterns can be differentiated from other skin malignancies by in vivo reflectance confocal microscopy. *J Eur Acad Dermatol Venereol*, 35: e784-e787.

131. Jobbágy A, Kiss N, Meznerics FA, Farkas K, Plázár D, Bozsányi S, Fésűs L, Bartha Á, Szabó E, Lőrincz K, Sárdy M, Wikonkál NM, Szoldán P, Bánvölgyi A. (2022) Emergency Use and Efficacy of an Asynchronous Teledermatology System as a Novel Tool for Early Diagnosis of Skin Cancer during the First Wave of COVID-19 Pandemic. *Int J Environ Res Public Health*, 19.
132. Clarke EL, Reichenberg JS, Ahmed AM, Keeling B, Custer J, Rathouz PJ, Jambusaria-Pahlajani A. (2021) The utility of teledermatology in the evaluation of skin lesions. *J Telemed Telecare*: 1357633x20987423.
133. Landis JR, Koch GG. (1977) The measurement of observer agreement for categorical data. *Biometrics*, 33: 159-174.
134. Moreno-Ramirez D, Ferrandiz L, Nieto-Garcia A, Carrasco R, Moreno-Alvarez P, Galdeano R, Bidegain E, Rios-Martin JJ, Camacho FM. (2007) Store-and-forward teledermatology in skin cancer triage: experience and evaluation of 2009 teleconsultations. *Arch Dermatol*, 143: 479-484.
135. Tharwat A. (2021) Classification assessment methods. *Applied Computing and Informatics*, 17: 168-192.
136. Fawcett T. (2006) An introduction to ROC analysis. *Pattern Recognition Letters*, 27: 861-874.
137. Zonios G, Dimou A, Bassukas I, Galaris D, Tsolakidis A, Kaxiras E. (2008) Melanin absorption spectroscopy: new method for noninvasive skin investigation and melanoma detection. *J Biomed Opt*, 13: 014017.
138. Ramanujam N. (2000) Fluorescence spectroscopy of neoplastic and non-neoplastic tissues. *Neoplasia*, 2: 89-117.
139. Bliznuks D, Jakovels D, Saknite I, Spigulis J. (2015) Mobile platform for online processing of multimodal skin optical images: Using online Matlab server for processing remission, fluorescence and laser speckle images, obtained by using novel handheld device. 2015 International Conference on BioPhotonics (BioPhotonics): 1-4.

140. Lihachev A, Derjabo A, Ferulova I, Lange M, Lihacova I, Spigulis J. (2015) Autofluorescence imaging of basal cell carcinoma by smartphone RGB camera. *J Biomed Opt*, 20: 120502.
141. Bozsányi S, Farkas K, Bánvölgyi A, Lőrincz K, Fésűs L, Anker P, Zakariás S, Jobbágy A, Lihacova I, Lihachev A, Lange M, Bliznuks D, Medvecz M, Kiss N, Wikonkál NM. (2021) Quantitative Multispectral Imaging Differentiates Melanoma from Seborrheic Keratosis. *Diagnostics (Basel)*, 11.
142. Bokolo Anthony J. (2020) Use of Telemedicine and Virtual Care for Remote Treatment in Response to COVID-19 Pandemic. *J Med Syst*, 44: 132.
143. Iyengar K, Mabrouk A, Jain VK, Venkatesan A, Vaishya R. (2020) Learning opportunities from COVID-19 and future effects on health care system. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*, 14: 943-946.
144. Colbert GB, Venegas-Vera AV, Lerma EV. (2020) Utility of telemedicine in the COVID-19 era. *Rev Cardiovasc Med*, 21: 583-587.
145. Kravets K, Vasylenko O, Dranyk Z, Bogomolets O. (2018) Store-and-forward teledermatology for the most common skin neoplasms in Ukraine. *Acta Dermatovenerol Alp Pannonica Adriat*, 27: 79-83.
146. Kroemer S, Frühauf J, Campbell TM, Massone C, Schwantzer G, Soyer HP, Hofmann-Wellenhof R. (2011) Mobile teledermatology for skin tumour screening: diagnostic accuracy of clinical and dermoscopic image tele-evaluation using cellular phones. *Br J Dermatol*, 164: 973-979.
147. Lamel SA, Haldeman KM, Ely H, Kovarik CL, Pak H, Armstrong AW. (2012) Application of mobile teledermatology for skin cancer screening. *J Am Acad Dermatol*, 67: 576-581.
148. Markun S, Scherz N, Rosemann T, Tandjung R, Braun RP. (2017) Mobile teledermatology for skin cancer screening: A diagnostic accuracy study. *Medicine (Baltimore)*, 96: e6278.
149. Giavina-Bianchi M, Azevedo MFD, Sousa RM, Cordioli E. (2020) Part II: Accuracy of Teledermatology in Skin Neoplasms. *Frontiers in Medicine*, 7.

150. Finnane A, Dallest K, Janda M, Soyer HP. (2017) Teledermatology for the Diagnosis and Management of Skin Cancer: A Systematic Review. *JAMA Dermatol*, 153: 319-327.
151. Silveira CE, Silva TB, Fregnani JH, da Costa Vieira RA, Haikel RL, Jr., Syrjänen K, Carvalho AL, Mauad EC. (2014) Digital photography in skin cancer screening by mobile units in remote areas of Brazil. *BMC Dermatol*, 14: 19.
152. Beer J, Haderl E, Nouri K. (2020) The Potential for Teledermatology in Managing and Diagnosing Patients With Cutaneous Lymphomas. *J Drugs Dermatol*, 19: 1125.
153. Knudsen KE, Willman C, Winn R. (2021) Optimizing the Use of Telemedicine in Oncology Care: Postpandemic Opportunities. *Clin Cancer Res*, 27: 933-936.
154. Rochette C, Michallet AS, Malartre-Sapienza S, Rodier S. (2021) Telephone follow-up of oncology patients: the contribution of the nurse specialist for a Service-Dominant Logic in hospital. *BMC Health Serv Res*, 21: 580.
155. Hsiao JL, Oh DH. (2008) The impact of store-and-forward teledermatology on skin cancer diagnosis and treatment. *J Am Acad Dermatol*, 59: 260-267.
156. Yeboah CB, Harvey N, Krishnan R, Lipoff JB. (2021) The Impact of COVID-19 on Teledermatology: A Review. *Dermatol Clin*, 39: 599-608.
157. Zakaria A, Miclau TA, Maurer T, Leslie KS, Amerson E. (2021) Cost Minimization Analysis of a Teledermatology Triage System in a Managed Care Setting. *JAMA Dermatol*, 157: 52-58.
158. Vidal-Alaball J, Garcia Domingo JL, Garcia Cuyàs F, Mendioroz Peña J, Flores Mateo G, Deniel Rosanas J, Sauch Valmaña G. (2018) A cost savings analysis of asynchronous teledermatology compared to face-to-face dermatology in Catalonia. *BMC Health Serv Res*, 18: 650.
159. Eminović N, Dijkgraaf MG, Berghout RM, Prins AH, Bindels PJ, de Keizer NF. (2010) A cost minimisation analysis in teledermatology: model-based approach. *BMC Health Serv Res*, 10: 251.
160. Carrera C. (2019) The Many Faces of Seborrheic Keratosis. *Actas Dermosifiliogr (Engl Ed)*, 110: 338.

161. Moreno-Ramírez D, Raya-Maldonado J, Morales-Conde M, Ojeda-Vila T, Martín-Gutiérrez FJ, Ruíz-de-Casas A, Fernández-Orland A, Jm HE, Ferrándiz L. (2017) Increasing Frequency of Seborrheic Keratosis Diagnoses as a Favorable Consequence of Teledermatology-Based Skin Cancer Screening: A Cross-sectional Study of 34,553 Patients. *Am J Clin Dermatol*, 18: 681-685.
162. Betlloch-Mas I, Martínez-Miravete MT, Berbegal-DeGracia L, Sánchez-Vázquez L, Sánchez-Payá J. (2021) Teledermatology in paediatrics: Health-care impact on the early treatment of infantile haemangiomas. *J Telemed Telecare*, 27: 424-430.
163. Warshaw EM, Gravely AA, Nelson DB. (2015) Reliability of store and forward teledermatology for skin neoplasms. *J Am Acad Dermatol*, 72: 426-435.
164. Young AT, Xiong M, Pfau J, Keiser MJ, Wei ML. (2020) Artificial Intelligence in Dermatology: A Primer. *J Invest Dermatol*, 140: 1504-1512.
165. Maier K, Zaniolo L, Marques O. (2022) Image quality issues in teledermatology: A comparative analysis of artificial intelligence solutions. *J Am Acad Dermatol*, 87: 240-242.
166. Jain A, Way D, Gupta V, Gao Y, de Oliveira Marinho G, Hartford J, Sayres R, Kanada K, Eng C, Nagpal K, DeSalvo KB, Corrado GS, Peng L, Webster DR, Dunn RC, Coz D, Huang SJ, Liu Y, Bui P, Liu Y. (2021) Development and Assessment of an Artificial Intelligence-Based Tool for Skin Condition Diagnosis by Primary Care Physicians and Nurse Practitioners in Teledermatology Practices. *JAMA Netw Open*, 4: e217249.
167. Izikson L, Sober AJ, Mihm MC, Jr, Zembowicz A. (2002) Prevalence of Melanoma Clinically Resembling Seborrheic Keratosis: Analysis of 9204 Cases. *Archives of Dermatology*, 138: 1562-1566.
168. Pathania YS, Apalla Z, Salerni G, Patil A, Grabbe S, Goldust M. (2022) Non-invasive diagnostic techniques in pigmentary skin disorders and skin cancer. *J Cosmet Dermatol*, 21: 444-450.
169. Hajian-Tilaki K. (2013) Receiver Operating Characteristic (ROC) Curve Analysis for Medical Diagnostic Test Evaluation. *Caspian J Intern Med*, 4: 627-635.



170. Park SH, Goo JM, Jo CH. (2004) Receiver operating characteristic (ROC) curve: practical review for radiologists. *Korean J Radiol*, 5: 11-18.
171. Hoo ZH, Candlish J, Teare D. (2017) What is an ROC curve? *Emerg Med J*, 34: 357-359.
172. Johansson M, Brodersen J, Gøtzsche PC, Jørgensen KJ. (2019) Screening for reducing morbidity and mortality in malignant melanoma. *Cochrane Database Syst Rev*, 6: Cd012352.
173. Bratchenko IA, Bratchenko LA, Khristoforova YA, Moryatov AA, Kozlov SV, Zakharov VP. (2022) Classification of skin cancer using convolutional neural networks analysis of Raman spectra. *Computer Methods and Programs in Biomedicine*, 219: 106755.
174. Piccolo D, Ferrari A, Peris K, Diadone R, Ruggeri B, Chimenti S. (2002) Dermoscopic diagnosis by a trained clinician vs. a clinician with minimal dermoscopy training vs. computer-aided diagnosis of 341 pigmented skin lesions: a comparative study. *Br J Dermatol*, 147: 481-486.
175. Christensen GB, Nagaoka T, Kiyohara Y, Johansson I, Ingvar C, Nakamura A, Sota T, Nielsen K. (2021) Clinical performance of a novel hyperspectral imaging device for cutaneous melanoma and pigmented skin lesions in Caucasian skin. *Skin Res Technol*, 27: 803-809.
176. Malvey J, Hauschild A, Curiel-Lewandrowski C, Mohr P, Hofmann-Wellenhof R, Motley R, Berking C, Grossman D, Paoli J, Loquai C, Olah J, Reinhold U, Wenger H, Dirschka T, Davis S, Henderson C, Rabinovitz H, Welzel J, Schadendorf D, Birgersson U. (2014) Clinical performance of the Nevisense system in cutaneous melanoma detection: an international, multicentre, prospective and blinded clinical trial on efficacy and safety. *Br J Dermatol*, 171: 1099-1107.
177. Ferrante di Ruffano L, Takwoingi Y, Dinnes J, Chuchu N, Bayliss SE, Davenport C, Martin RN, Godfrey K, O'Sullivan C, Gulati A, Chan SA, Durack A, O'Connell S, Gardiner MD, Bamber J, Deeks JJ, Williams HC. (2018) Computer-assisted diagnosis techniques (dermoscopy and spectroscopy-based) for diagnosing skin cancer in adults. *Cochrane Database Syst Rev*, 12: Cd013186.

178. Izikson L, Sober AJ, Mihm MC, Jr., Zembowicz A. (2002) Prevalence of melanoma clinically resembling seborrheic keratosis: analysis of 9204 cases. *Arch Dermatol*, 138: 1562-1566.
179. Hosking AM, Coakley BJ, Chang D, Talebi-Liasi F, Lish S, Lee SW, Zong AM, Moore I, Browning J, Jacques SL, Krueger JG, Kelly KM, Linden KG, Gareau DS. (2019) Hyperspectral imaging in automated digital dermoscopy screening for melanoma. *Lasers Surg Med*, 51: 214-222.
180. Apalla Z, Nashan D, Weller RB, Castellsagué X. (2017) Skin Cancer: Epidemiology, Disease Burden, Pathophysiology, Diagnosis, and Therapeutic Approaches. *Dermatol Ther (Heidelb)*, 7: 5-19.
181. Pil L, Hoorens I, Vossaert K, Kruse V, Tromme I, Speybroeck N, Annemans L, Brochez L. (2017) Cost-effectiveness and Budget Effect Analysis of a Population-Based Skin Cancer Screening. *JAMA Dermatol*, 153: 147-153.
182. Køster B, Meyer MKH, Andersson TM, Engholm G, Dalum P. (2019) Skin cancer projections and cost savings 2014-2045 of improvements to the Danish sunbed legislation of 2014. *Photodermatol Photoimmunol Photomed*, 35: 78-86.
183. Schneider SL, Kohli I, Hamzavi IH, Council ML, Rossi AM, Ozog DM. (2019) Emerging imaging technologies in dermatology: Part I: Basic principles. *J Am Acad Dermatol*, 80: 1114-1120.
184. Arzberger E, Curiel-Lewandrowski C, Blum A, Chubisov D, Oakley A, Rademaker M, Soyer H, Hofmann-Wellenhof R. (2016) Teledermoscopy in High-risk Melanoma Patients: A Comparative Study of Face-to-face and Teledermatology Visits. *Acta Derm Venereol*, 96: 779-783.
185. Loh CH, Chong Tam SY, Oh CC. (2021) Teledermatology in the COVID-19 pandemic: A systematic review. *JAAD Int*, 5: 54-64.
186. Kim S, Kim J, Hwang M, Kim M, Jin Jo S, Je M, Jang JE, Lee DH, Hwang JY. (2019) Smartphone-based multispectral imaging and machine-learning based analysis for discrimination between seborrheic dermatitis and psoriasis on the scalp. *Biomed Opt Express*, 10: 879-891.

## 9. Bibliography of the candidate's publications

### 9.1. Publications directly related to this thesis

1. **Jobbágy A**, Kiss N, Meznerics F A, Farkas K, Plázár D, Bozsányi S, Fésűs L, Bartha Á, Szabó E, Lőrincz K, Sárdy M, Wikonkál NM, Szoldán P, Bánvölgyi A. (2022) Emergency Use and Efficacy of an Asynchronous Teledermatology System as a Novel Tool for Early Diagnosis of Skin Cancer during the First Wave of COVID-19 Pandemic. *Int J Environ Res Public Health*, 19(5):2699. **IF: 3.390**
2. Bozsányi S, Farkas K, Bánvölgyi A, Lőrincz K, Fésűs L, Anker P, Zakariás S, **Jobbágy A**, Lihacova I, Lihachev A, Lange M, Bliznuks D, Medvecz M, Kiss N, Wikonkál NM. (2021) Quantitative Multispectral Imaging Differentiates Melanoma from Seborrheic Keratosis. *Diagnostics*, 11(8):1315. **IF: 3.706**
3. **Jobbágy A**, Meznerics F A, Farkas K, Plázár D, Bozsányi Sz, Fésűs L, Róbert L, Schweibert Á, Kuzmanovszki D, Szoldán P, Lőrincz K, Kiss N, Wikonkál N, Sárdy M, Bánvölgyi A. (2022) Teledermatology: the new era of digitalization in dermatology care. *Bőrgyógyászati és Venerológiai Szemle*, 98(3):100-107. **IF:-**

### 9.2. Publications not related to this thesis

1. Polak K, **Jobbágy A**, Muszyński T, Wojciechowska K, Frątczak A, Bánvölgyi A, Bergler-Czop B, Kiss N. (2021) Microbiome Modulation as a Therapeutic Approach in Chronic Skin Diseases. *Biomedicines*, 9(10):1436. **IF: 6.081**
2. Lőrincz K, Meznerics F A, **Jobbágy A**, Kiss N, Madarász M, Belvon L, Tóth B, Tamási B, Wikonkál N M, Marschalkó M, Bánvölgyi A. (2022) STIs during the COVID-19 Pandemic in Hungary: Gonorrhoea as a Potential Indicator of Sexual Behavior. *Int J Environ Res Public Health*, 19(15):9627. **IF: 4.614**
3. Virág D, Kremmer T, Lőrincz K, Kiss N, **Jobbágy A**, Bozsányi S, Gulyás L, Wikonkál N, Schlosser G, Borbély A, Huba Z, Dalmadi Kiss B, Antal I, Ludányi K. (2021) Altered Glycosylation of Human Alpha-1-Acid Glycoprotein as a Biomarker for Malignant Melanoma. *Molecules*, 26(19):6003. **IF: 4.412**

4. Bozsányi S, Varga NN, Farkas K, Bánvölgyi A, Lőrincz K, Lihacova I, Lihachev A, Plorina EV, Bartha Á, **Jobbágy A**, Kuroli E, Paragh G, Holló P, Medvecz M, Kiss N, Wikonkál NM. (2021) Multispectral Imaging Algorithm Predicts Breslow Thickness of Melanoma. *J Clin Med*, 11(1):189. **IF: 4.242**
5. Fésűs L, **Jobbágy A**, Kiss N, Horváth E, Avci P, Lukács A, Mayer K, Bergler-Czop B, Wikonkál N, Bánvölgyi A. (2021) Dermatologic aspects of bed bug epidemic: an atlas of differential diagnosis. *Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii*, 38:184-192. **IF: 1.837**
6. **Jobbágy A**, Fésűs L, Kiss N, Lőrincz K, Sárdy M, Wikonkál N, Bánvölgyi A. (2020) Hyperhidrosis: clinical classification and treatment options. *Bőrgyógyászati és Venerológiai Szemle*, 96(1):36-43. **IF: -**
7. Fésűs L, Kiss N, **Jobbágy A**, Farkas K, Meznerics F, Bozsányi Sz, Bánvölgyi A, Wikonkál N, Lőrincz K. (2022) Innovative in vivo imaging techniques in dermatology. *Bőrgyógyászati és Venerológiai Szemle*, 98(3):133-141. **IF: -**
8. Szalai K, Farkas K, Gergely H, Varga NN, Magyar M, Nagy Z Zs, Fésűs L, Bozsányi Sz, **Jobbágy A**, Medvecz M, Bánvölgyi A, Lőrincz K, Wikonkál N, Kiss N. (2022) Clinical application of high-frequency ultrasound, optical coherence tomography and magnetic resonance imaging in dermatology, *Bőrgyógyászati és Venerológiai Szemle*, 98(3):125-132. **IF: -**

## 10. Acknowledgement

At the end of my doctoral thesis, I would like to express my thanks and appreciation to all those people whose help was essential to my scientific work.

First of all, I would like to express my deepest gratitude to my supervisors. I am really fortunate that I had a dermatology tutor as Professor Norbert Wikonkál, when I was a fourth year medical student. He introduced me to this extremely complex and rapidly evolving specialty. I am honored that he allowed me start my research in his laboratory. His advices and valuable comments have guided me throughout my work and helped my development to practice science to a high standard. I would like to thank Dr. András Bánvölgyi for his patience and guidance. He has encouraged me, inspired me and gave me confidence to walk the path of a researcher. His exemplary attitude and knowledge have greatly assisted my professional development. Without his innovative mindset, my PhD thesis and teledermatology care during the first wave of the COVID-19 pandemic would not have been possible.

I would like to thank Professor Miklós Sárdy. As the previous chair of the Department, he allowed me to start my research career. I am grateful that he let teledermatology care to start at the Department and experience such an innovative way of science.

I would like to express my thanks to the present chair of the Department, Professor Péter Holló for the great support and advices. I am grateful that he gave me the possibility to expand my knowledge and continue my carrier at the Department.

I would like to thank the senior members of our labor who helped me with their outstanding skills and knowledge. I am honored to be supported by Dr. Norbert Kiss, who helped my work with great ideas and excellent precision. I would like to acknowledge Dr. Kende Lőrincz, who gave me guidance and selfless support in the field of science and life as well.

Furthermore, I also share the credit for this with Dr. Szabolcs Bozsányi. He is one of the most motivational people I have ever met. Our friendship has been one of the greatest points of the medical school and research years.

I owe a debt to my PhD colleague, Dr. Fanni Meznerics, who helped my work with unselfish dedication and excellent precision. I would like to thank my other PhD and resident doctor colleagues, Dr. Klára Farkas, Dr. Dóra Plázár, Dr. Sára Pálla, Dr. Luca Fésűs and Dr. Pálma Anker. Special thanks to our student researchers, István Szondy, Noémi Nóra Varga, Jázmin Shamsodini, Natália Czurkó, Lili Gulyás and Maxime Buitendijk.

I also express my deepest thanks to Professor Sarolta Kárpáti, Dr. Márta Medvecz, Dr. Bernadett Hídvégi, Dr. József Szakonyi, Dr. Anikó Kovács, Dr. Anna Görög, Dr. Veronika Tóth, Dr. Béla Tóth, Dr. Béla Tamási, Dr. Adrienn Poór, Dr. Pálma Silló, Dr. Alexandra Brunner, Dr. Melinda Fábián, Dr. Hunor Gergely, Dr. Krisztina Becker, Dr. Klaudia Preisz, Dr. Anita Mohos, Dr. Péter Bognár, Dr. Kincső Blága, Dr. Tünde Kerner, Dr. Lili Róbert, Dr. Béla Háromszéki, Dr. Csilla Györbíró, Dr. Ivett Dobribán-Ónodi, Dr. Csilla Haász, Dr. Andrea Gál, Dr. Franciska Somogyi, Dr. László Fazekas, Dr. Martina Kádas, Dr. Andrea Litskay, Dr. Dóra Faluhelyi, and Dr. Dóra Beke. I express my deepest gratitude to Nóra Talmaci and Mercédesz Mazán, as well. They took part in teledermatology care during the first wave of the COVID-19 pandemic.

I am deeply grateful to the MedInnoScan Research and Development Ltd., which developed and provided the teledermatology system to our Department. I would like to specially thank their chief executive officer, Péter Szoldán, who facilitated the organization and development of the teledermatology system. I greatly appreciate the contribution of Veronika Orbán, Dóra Török, and Éva Fekete-Tóth, who provided continuous IT support for dermatologists and patients, performed ongoing administrative tasks and testing.

I would like to thank Ilze Lihacova, Alexey Lihachev, Emilija Vija Plorina, Marta Lange, Dmitrijs Bļizņuks, Emilija Vija Plorina and the University of Latvia for the development of the LED device.

Finally, I would like to thank my family, friends and the Fellowship of Room 215, who have stood by me through the hard times. Their deepest patience and unselfish dedication to support me always served as a reminder why I chose this path. Special thanks to my nephew who have encouraged me to never give up and pushed forward.